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ABSTRACT OF DISSERTATION 
 
 
IMMUNOTHERAPY IN COMBINATION WITH BEHAVIORAL 
ENRICHMENT IN A CANINE MODEL OF AGING 
  
Alzheimer’s disease (AD) is characterized by cognitive decline and hallmark 
neuropathology, including β-amyloid (Aβ).  Therapeutic strategies for AD are 
focusing on reducing Aβ.  Canines develop Aβ neuropathology and cognitive 
decline with age similar to AD patients.  In previous studies, immunization with 
Aβ1-42 (VAC) in aged canines decreased brain Aβ but did not improve cognition.  
Behavioral enrichment (ENR) improved cognition without reducing brain Aβ.  We 
hypothesized that VAC combined with ENR would provide cognitive benefits and 
reduce Aβ neuropathology, as compared individual VAC and ENR treatments.  
Aged beagles were placed into groups: control, VAC with fibrillar Aβ1-42, ENR, 
and combination treatment (VAC+ENR) for 18 months. Learning and memory was 
evaluated throughout the study.  Serum IgG antibody titers, cerebral spinal fluid 
(CSF) and brain Aβ were measured. Serum anti-Aβ1-42 IgG increased 
significantly in VAC animals.   ENR but not VAC significantly increased CSF Aβ1-
40.  No cognitive improvements were observed in any group. VAC significantly 
reduced brain Aβ1-40 and 1-42, as well as reduced plaque load.  An overall 
slowing of plaque accumulation was seen in the ENR group. VAC and ENR were 
able to modify pathology when used as separate treatments; however, the 
combination treatment did not succeed in further reducing Aβ or improving 
cognition.  Previous AD clinical trials using immunotherapy yielded similar 
outcomes to our study showing reduced Aβ pathology but little to no cognitive 
improvements.  In combination these results suggest that future studies should 
focus on prevention approaches both in the canine model and in human clinical 
trials. 
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CHAPTER ONE: Alzheimer’s disease 
Frequency of Alzheimer’s disease in the US and Internationally 
In the United States, 5.4 million people are living with Alzheimer disease 
(AD), (178, 495, 496).  The number of people living with the disease is expected 
to triple by 2050.  This increase in prevalence of AD is thought to be due to the 
general population living longer as well as the “baby boom” generation reaching 
the age of 75, a time at which the most common late onset of the disease is seen 
(22, 323).  AD occurrence increases exponentially between the ages of 75 and 85 
with about 50% of the population over the age of 85 being affected (113, 121, 178).  
In 2010, the Center for Disease Control and Prevention reported 83,494 deaths 
due to AD.  However, a recent study by James et al. indicated the death toll may 
be closer to 500,000 placing AD as the 3rd top killer in the US as opposed to its 
previous place at 6th.  Only heart disease and cancer are higher than AD in number 
of deaths per year (197). 
Economic Impact 
Not only is the prevalence and number of deaths caused by AD increasing, 
but the global economy is significantly impacted.  The estimated annual global 
economic burden due to dementia is between $315 and $604 billion (189, 486).  
These vast costs come as little surprise with 12% of the population being elderly, 
of whom make up 26% of physician visits, one third of hospital stays and 
prescriptions, 40% of emergency responses, and 90% of nursing home residents 
(22).  These numbers will only grow as noted earlier due to the aging “baby boom” 
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population.  By 2029, all “baby boomers” will be at least 65 years old totaling an 
estimated 70 million people in the US aged 65 years and older.   
In 2009, the Alzheimer’s Association totaled direct costs to Medicare and 
Medicare as well as indirect costs to businesses for employees who are caregivers 
of individuals with AD and other dementias to be estimated at more than $203 
billion in 2013 and expected to increase to $1.2 trillion in 2050 (23, 150, 224).  In 
2008, the average individual out of pocket costs for Medicare beneficiaries over 
the age of 65 with AD and other dementias was $9,754 per person per year for 
healthcare and long-term care services, with the payments being highest for those 
living in nursing homes and assisted living facilities (22, 23).  The total costs in 
2004 from all sources of hospice care for these beneficiaries totaled $2.8 billion 
(22).  In addition to these expenses, are those that were not paid to individuals 
who voluntarily cared for those with dementia.  Whether it was family, a friend, or 
neighbor, over 15 million people provided unpaid care for an individual with AD or 
other dementia in 2008 (9, 22, 23).  In 2012, these caregivers totaled 17.5 billion 
(22, 448).  The time provided by these caregivers is valued at $216 billion dollars 
(22, 448).  For perspective, the value of caregiver time totaled in 2011 equaled half 
the net sales from Walmart and eight times the sales of McDonald’s (448).   While 
AD is quickly becoming an epidemic among the elderly, so has the cost of care for 
these individuals on the US economy. 
History 
AD was first described in1906, by Dr. Alois Alzheimer after treating a patient 
who exhibited progressive memory decline (10).  Augusta Deter, a 51 year-old 
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woman, died 5 years later after she was first seen by Dr. Alzheimer  (10, 431).   It 
was noted at autopsy that the patient’s cerebral cortex was atrophied (10). At this 
time, Alzheimer also identified histopathological changes that would later come to 
be known as the hallmark lesions of AD, neuritic plaques and neurofibrillary tangles 
(NFTs).  In 1910, Emil Kraepelin named presenile dementia “Alzheimer’s disease” 
to honor Alois Alzheimer (395, 431).   A clinical diagnosis of AD is made when a 
patient exhibits dementia with progressive decline, although a final diagnosis of 
AD cannot be confirmed until post mortem examination and requires the presence 
of AD pathological findings (96).       
Cognitive and Behavioral Changes 
A diagnosis of dementia is established when an individual exhibits the loss 
of 2 or more of the following cognitive domains: memory, language, calculation, 
orientation, or judgment (1, 2).  However, for the individual to have a “probable AD” 
diagnosis, they must have dementia that is clinically documented along with 
deficits in at least 2 cognitive domains, absence of other systemic disorders, and 
progressive worsening of memory (269, 270, 336, 338).    Individuals with AD show 
difficulty remembering new information and exhibit confusion, disorganized 
thinking, impaired judgment, and disorientation with time, space and location.    In 
addition, those with AD experience frequent changes in mood, are easily agitated, 
and often experience anxiety.  These psychological changes often lead to 
restlessness and sleep deprivation (12, 208, 285).  Most AD patients require 
assistance with bathing, dressing, using the bathroom, eating, and other daily 
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activities.  The gradual decline in memory eventually increases in severity until the 
symptoms become debilitating (35).     
If not noted by patient report or by a family member, friend, or caregiver, the 
first signs of cognitive impairment can be detected through direct observation by a 
clinician during an Annual Wellness Visit (15).  If symptoms of cognitive impairment 
are present, a brief structured patient assessment of cognition is performed using 
one of several available tools including the Mini-Mental State Examination 
(MMSE), the Memory Impairment Screen (MIS), the General Practitioner 
Assessment of Cognition (GPCOG), or the Mini-Cog (59, 183, 192, 249, 281).  In 
addition, informant assessments of the patient can be conducted using the 
GPCOG, AD8, or short Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE).  If any of these assessments indicate possible cognitive impairment, a 
full dementia evaluation can be conducted and may include an assessment of 
multiple cognitive domains, a neurologic exam, standard laboratory tests, and 
structural brain imaging. Results of a full dementia evaluation will help determine 
an appropriate diagnosis such as mild cognitive impairment or AD, or determine 
other possible causes (75). 
Familial and Sporadic Alzheimer’s disease 
There are two types of AD, familial and sporadic.  When at least two 
generations of a family has been reported to have AD with a mutation that is 
inherited, it is considered of the familial type (41, 303). Sporadic AD occurs with 
some genetic or outside contributing factors increasing one’s risk.    AD is further 
defined as being early (EOAD) or late onset (LOAD) based on the age of onset of 
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the disease.  EOAD occurs before the age of 65 and LOAD occurs after (37, 497).  
Almost all cases of sporadic AD are LOAD.  EOAD makes 1-6% of AD cases of 
which 60% are familial AD (57, 63).  While familial AD must have a genetic 
component, sporadic forms of AD may also have a genetic component (76, 77, 
333, 350-355).  However, a majority of the cases are unpredictable with various 
factors including past medical history, environment, and lifestyle factors that may 
increase or decrease the risk of AD and the age of onset.   
Genetic Contributions to AD 
Of the 60% familial cases that are EOAD, 13% are due to autosomal 
dominant inheritance of specific genes (57, 63).  Researchers have found several 
genes to be associated with AD, but the three most commonly linked to familial 
EOAD include mutations on the amyloid precursor protein (APP), presenilin 1 
(PSEN1), and presenilin 2 (PSEN2) genes (141, 243, 244, 348, 349, 397).  Over 
200 mutations are reported in these three genes alone (35).   A consistent feature 
of all these mutations is elevated Aβ peptide levels (discussed in more detail later), 
enhanced aggregation of Aβ, early onset of AD neuropathology, and cognitive 
decline (25).  The APP gene encodes an integral type 1 membrane glycoprotein 
and when cleaved by beta and gamma secretases results in different Aβ peptide 
isoforms.  Mutations in APP result in altered ratios of Aβ isoforms in the brain and 
can account for 10-15% of familial autosomal dominant EOAD cases (157, 339).  
The PSEN1 and PSEN2 genes encode two proteins that are components of the 
gamma-secretase complex, which are expressed in many different tissues 
including the brain and are involved in cleaving APP to Aβ (242-244, 348).  APP 
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processing will be discussed in further detail in Chapter 2.  The mutations reported 
in PSEN1 and PSEN2 may result in a modified gamma secretase cleavage of APP. 
This altered cleavage activity leads to altered Aβ ratios with an increase in AB1-42 
(107). PSEN1 accounts for a majority of the reported mutations and is the most 
common cause of familial EOAD making up 18-50% of the autosomal dominant 
cases (382, 432, 447). 
Only one gene has been widely studied as the strongest risk factor for 
sporadic LOAD, apolipoprotein E (APOE).  APOE is a three-allele polymorphism 
(ε2, ε3, ε4) encoding for a glycoprotein that carries cholesterol in the blood stream 
and maintains lipid metabolism and transport (22, 76, 77, 349, 402).  Additionally 
it can influence the clearance of cerebral Aβ in AD individuals (76, 77).  The effect 
APOE has on AD depends on which alleles are expressed.  ApoE2 has exhibited 
protective properties and can act on longevity, ApoE4 increases the risk of AD, 
and ApoE3 is considered neutral (76, 77).  Humans express two alleles of APOE.  
The effects of the two alleles a person expresses act in a dose dependent manner 
(76, 77). For example, having at least one ApoE4 allele leads to a higher risk of 
developing LOAD compared to individuals with no ApoE4 allele. However, the risk 
of AD is 15 fold higher in homozygous carriers of ApoE4 (21).  Individuals with 
ApoE4 show more Aβ and NFT pathology when compared to individuals with other 
ApoE allele expression (35). The risk of developing AD by ApoE genotype can be 
modified further by non-genetic factors such as head trauma or stroke (184, 185, 
300). The frequencies and distribution of the ApoE alleles vary widely among 
populations (504, 505) however the ApoE3 allele is the most commonly expressed 
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(35).  APOE, along with APP, PSEN1, and PSEN2 make up less than 30% of the 
genetic variance in EOAD and LOAD, however,  many other genes are currently 
being studied and reported (89, 431). 
Non-Genetic Contributions 
While APOE can influence risk of LOAD, other non-genetic variables can 
increase, or decrease risk as well.  Risk of AD increases with age, female gender, 
and lower education (121, 236, 430).  Females have a risk of AD three times higher 
than that of males (125).  This may be due to the fact that women on average live 
longer than men, allowing more time for the development of AD (22).  Education 
is an important factor influencing risk of AD (210-212, 421, 422, 506).  The 
supporting idea for this risk is that individuals with higher education develop a 
greater “cognitive reserve capacity” than those with lower education (422).  By 
having a greater reserve, a maintenance of cognition or delay of dementia onset 
may occur as a consequence of  compensating for any functional deficits caused 
by AD pathology (11).   
Comorbidities can also influence AD risk.  Individuals with systemic 
hypertension, diabetes mellitus, cardiovascular disease, and cerebrovascular 
disease all experience a greater risk for developing AD (191, 229, 251, 265, 306, 
412).  Those with type II diabetes have a two-fold increased risk for AD (117, 250, 
251, 317).  Middle-aged individuals with high serum cholesterol levels are also at 
a higher risk of AD later in age (220, 481).  Observational studies have shown mid-
life hypertension to increases likelihood of AD (267).  However, low blood pressure 
later in life can also increase chances of developing AD (334, 356).  History of 
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traumatic brain injury or stroke dramatically increases risk of AD (122, 318), 
especially in APOE4 carriers.  Some environmental factors that also appear to 
contribute to risk of AD include lack of social engagement, smoking, and heavy 
alcohol drinking. Individuals who are ApoE4 carriers are especially affected by 
smoking and heavy drinking (4, 16, 273, 311).    
Protective Factors 
While there are several factors that increase the risk of developing AD, there 
are also several that are associated with reduced risk of disease including social 
and cognitive enrichment, physical activity, and diet (112, 372, 373, 466).  Exercise 
activates neural plasticity, remodels neuronal circuitry, and promotes 
vascularization (38, 80, 462).   Cognitive enrichment such as reading, social 
activities, knitting, tabletop games, information processing activities, and playing 
musical instruments have all shown to be protective and reduce risk of dementia 
and AD (36, 84).  Diet has been widely studied for protective factors against the 
development of sporadic AD.  Omega-3, vitamin D, and folic acid have all been 
shown to reduce risk of AD (110, 289-292, 374, 472).  In addition, several studies 
suggest that a Mediterranean diet of vegetables, legumes, fruits, and cereals, 
unsaturated fats, fish, some dairy, meat and poultry, and wine is also associated 
with decreased risk (415).  While genetic factors and medical history can influence 
the onset of AD, there are many lifestyle practices an individual can engage in to 
reduce their risk. 
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Neuropathology of AD 
In parallel, or prior to, the development of cognitive and behavioral changes, 
individuals with AD accumulate several types of neuropathology that become 
progressively worse as the disease evolves.  In the 1960’s, the 2 classic lesions of 
AD, NFTs and senile plaques, were confirmed as hallmark pathology for the 
disease (215, 431).  During the 1980s, various neurotransmitter deficits were 
identified in AD (146, 147, 298, 329).  Additional forms of neuropathology that 
contribute to AD have also been described including changes in brain volume, 
synaptic and neuronal loss, as well as decreased neurogenesis. A brief description 
of each of these key pathologies is described next. 
Brain Volume and Neuronal Loss  
The medial temporal lobe, including the hippocampus and entorhinal cortex, 
is the first area in the brain to show atrophy in individuals with AD and occurs early 
in the disease as shown with structural MRI (26, 48, 52, 106, 216, 337, 414, 449, 
450).  Atrophy, including loss of myelination, synapses, and  neurons, begins in 
the temporal lobe and develops into the neocortex, notably the frontal and parietal 
regions, at later stages of the disease (26, 48, 52, 73, 90, 106, 188, 195, 284, 380, 
414, 449).  Several longitudinal studies have shown that increased rates of 
ventricular widening as well as regional and whole brain atrophy in otherwise 
healthy individuals increases risk of developing cognitive decline due to AD later 
in life (64, 196, 357).  Several studies have indicated a strong correlation between 
cognitive ability and synaptic numbers (93, 247, 369, 375, 377-379, 441).  With the 
loss of synaptic contacts and neurons, a significant reduction of grey matter in the 
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hippocampus and entorhinal cortex is seen in later stages of AD (308). This grey 
matter loss correlates with decreased cognitive performance, especially so with 
memory (227, 439).  However, synaptic and neuronal loss is experienced in 
multiple regions of the brain in AD, possibly explaining the diverse cognitive 
changes seen with the progression of the disease (376). 
Neurogenesis 
Neurogenesis takes place primarily in two regions of the adult brain, the 
subgranular zone of the dentate gyrus of the hippocampus and subventricular zone 
of the lateral ventricles (111).  Fully functioning neurons can be generated from 
progenitor cells. These cells proliferate into immature neurons and migrate to the 
granule cell layer where they mature and integrate into preexisting circuitry (502).  
Interestingly, several genetic contributors to familial AD modulate neurogenesis, 
including PS1 and APP (237).  While PS1 positively regulates neural progenitor 
cell differentiation, soluble APP positively regulates proliferation (62, 126, 127, 
238).  However, mutations in these two genes, as seen in familial AD, alter alpha 
and gamma secretase activity and reduce soluble APP, respectively, which may 
suppress neurogenesis (as reviewed in (237)).  These deficiencies in 
neurogenesis may occur early in  AD, prior to plaques, NFT, or neuronal loss, thus 
further supporting the idea that familial AD involved proteins directly affect 
neurogenesis which may contribute to the development of  AD (238).   
The link between changes in learning and memory with age and losses in 
neurogenesis is complex (237).  The hippocampus is one of the first regions of the 
brain affected in AD, and is also one of only two brain regions where neurogenesis 
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occurs. Thus supporting the hypothesis that pathological processes of AD impact 
neurogenesis, and vice versa (161, 205, 206, 248, 386, 467, 468, 508).  It has 
been proposed that when these disease processes begin to take place, rates of 
neurogenesis will increase in attempt to compensate before a significant loss in 
neurogenesis is observed (5, 222, 228, 248, 399, 400). Decreases in neurogenesis 
may underlie cognitive impairments associated with dementia (69, 161, 205, 206, 
237, 248, 386, 467, 468, 508).  Suppressing neurogenesis causes deficits in 
hippocampal dependent learning; while other cognitive domains appear unaffected 
(238, 507).  Furthermore, additional studies that increase neurogenesis in mice 
lead to improved performance in pattern separation and spatial memory (363, 
423).   
Neurofibrillary Tangles 
In 1963, neurofibrillary tangles (NFTs) were first identified as one of the 
hallmark lesions of AD and found to be made up of paired helical filaments (PHFs) 
(190, 215, 431). Then in 1986, researchers found that NFTs were comprised of 
microtubule associated protein tau (58, 151, 225, 304, 494).  Tau protein has a 
normal function of stabilizing microtubule formation and disassembly in neurons.  
In its non-phosphorylated state, tau protein binds microtubules and binds less 
tightly once phosphorylated (56).  However, increased phosphorylation, or hyper-
phosphorylation, of tau can lead to aggregation of the protein within the cell and 
formation of paired helical filaments (PHF) (151). Ultimately these PHFs lead to 
the formation of neurofibrillary tangles (NFT) (142, 226, 240, 264).  There are 19 
specific amino acid sequences that are frequently phosphorylated in the formation 
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of NFTs in AD (29, 142, 226, 240, 264).  Tau protein can be phosphorylated by 
several kinases, but the three commonly acting on phosphorylation sites of interest 
in AD include MAP kinase, GSK-3 and cdk5 (104, 254). 
The extent and distribution of NFTs correlates with the severity of dementia 
in AD (20, 49).  There are different morphological stages of NFTs including pre-, 
intra-, and extra- neuronal (219).  Pre-neuronal NFTs include intracellular punctate 
aggregates of hyperphosphorylated tau inside an otherwise healthy neuron.  Once 
these aggregates start to form filamentous structures, paired helical filaments 
(PHFs), an NFT is then considered intra-neuronal.  NFTs enter the final 
morphological stage, extra-neuronal, when the neuron dies and only an extra 
cellular NFT, or “ghost tangle”, remains (219).  
In addition to morphological changes, NFTs have defined stages for 
progression in terms of severity and location within the brain known as Braak 
stages I-VI (19, 52).  A 900 autopsy case study spanning the ages 25 to 95 of 
demented and non-demented brains showed that younger cases showed a pattern 
of NFT deposition that spread with more advanced ages (307).  NFTs are first 
observed in layer II of the entorhinal cortex (transentorhinal cortex) following a 
predictable sequence spreading onward to other regions of the brain (19, 20, 50, 
53, 187, 326, 460, 461).  Braak stages I and II are defined as having NFTs present 
in the transentorhinal region of the brain with the absence of cognitive impairments 
(55, 200).  At these stages, this area is generally void of any Aβ deposits of plaques 
(54).  Progression into Braak stages III and IV show more extensive NFT pathology 
into the hippocampus, however, most of the neocortex is unaffected.   When NFTs 
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reach the hippocampus, limbic circuits become disrupted that is associated with 
declines in cognition seen at these stages.  This disruption is further exacerbated 
in Braak stages V and VI when NFTs are prevalent throughout the cerebral cortex.  
These stages of neuropathology are used for confirmation of clinical AD diagnosis 
(283, 451).  NFTs have been seen in other neurodegenerative diseases in the 
absence of Aβ pathology, and it can be assumed that NFTs can occur 
independently of plaques in the progression of AD (389).  This is seen in Braak 
stages I and II of NFT progression.  However, for a final diagnosis of AD, the 
presence of senile plaques is also required. 
β-Amyloid 
In addition to NFTs, a final diagnosis of AD at post mortem examination also 
requires the presence of Aβ plaques (33, 96, 201).  As with most of the 
neuropathology observed in AD, Aβ pathology occurs early in the disease before 
cognitive impairments are observed (389).  Genetic mutations of APP, PSEN1, or 
PSEN2 seen in familial AD can influence the age at which Aβ pathology is first 
seen.  According to the amyloid cascade hypothesis, excess accumulation of Aβ 
peptide induces a series of events including the formation of insoluble and soluble 
oligomers followed by aggregate stress, the formation of NFTs, and ultimately 
leading to neuronal death and AD (159).  At the start of the cascade, APP is 
cleaved by β- and γ- secretase and the resultant cleavage product is the Aβ 
peptide (476).  Depending on the location at which γ- secretase cleaves APP, 
various species of Aβ peptide can be produced. The two most common Aβ peptide 
species are Aβ1-40 and Aβ1-42 (194, 389). These Aβ peptides can accumulate into 
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oligomers, then fibrils,  which then aggregate further to make up Aβ plaques (97, 
138, 261).  The spatial pattern of Aβ deposition begins in the frontal cortex 
spreading to the lateral and parietal regions early in the disease (18, 50-52, 445). 
Later, Aβ deposition spreads further into the occipital lobe and motor cortices with 
the entorhinal cortex and hippocampal region being affected last (18, 51). Whether 
Aβ deposition directly causes neuronal loss is unknown, but Aβ  is toxic and can 
alter neuron function (294).  For example, many studies have shown Aβ deposition 
impairs long term potentiation, a physiological substrate for memory, and neuronal 
plasticity in the hippocampus (245, 389). 
The extent of Aβ pathology including peptide production and isoforms, the 
various types of plaques that form, and effects on cognition will be described in 
greater detail in the following chapter.   
Vascular Aβ and Cerebral Amyloid Angiopathy 
In addition to Aβ plaques, Aβ peptides can deposit in association with the 
vasculature (138).   Aβ was originally isolated from meningeal blood vessels of 
individuals with Down syndrome and AD (138, 139).  Aβ deposition in vascular 
walls is characteristic of cerebral amyloid angiopathy (CAA) (138, 389).  CAA is 
defined as amyloid protein aggregated within the blood vessels of brain tissue that 
can be stained by Congo red, an immunohistochemical stain that labels compacted 
amyloid protein aggregates (342).  While Aβ protein makes up Aβ plaques and 
CAA, there is a low correlation between the two events and each can occur in 
absence of the other (389, 465).  Population studies show that 55-59% of patients 
with dementia show CAA and in up to 98% of the AD cases (199, 214).  Though 
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the majority of the AD population shows CAA in the brain, the degree of CAA 
burden among individuals with AD can vary widely (389, 465).  Genetic mutations 
associated with AD, including APOE and PSEN1, are also risk factors for CAA 
deposition (149, 299, 325, 499).  While CAA can be found throughout the brain, 
the distribution pattern is much like that of Aβ plaques beginning in the frontal, 
parietal, temporal, and occipital cortices and later in the hippocampus and 
entorhinal cortex (443, 444).  Interestingly, a study documenting and assessing 
various forms of neurodegenerative pathology in relation to cognitive function 
indicated that CAA may correlate more strongly with the presence of dementia 
than with other forms of amyloid pathology (266). However, the contribution of CAA 
to dementia is not well understood (465).   
Accumulation of Aβ in the vasculature may be due to efforts of clearing the 
peptide from the brain or microglial uptake and deposition into the vascular lumen.  
Vascular Aβ deposition prompts smooth muscle cells of these vessels to produce 
vascular Aβ, allowing further Aβ deposition. Affected vessels show thickened walls 
with amyloid deposits and degeneration of smooth muscle cells (260, 301).  On 
rare occasion, advanced CAA damage of the vessel walls can cause them to 
rupture resulting in microhemorrhages or hemorrhagic stroke (389, 489).  When 
hemorrhaging does occur, it is predominantly located in the frontoparietal, 
temporal, and occipital regions of the brain.  A definitive clinical diagnosis of CAA-
related hemorrhages cannot be made until postmortem examination, but a 
probable diagnosis can be made by MRI or CT imaging (223).  In comparison, a 
probable diagnosis of CAA can be made with the observation of multiple 
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hemorrhages confined to lobar brain areas with no other explanation for the 
pathology (148).  Cerebral microhemorrhages are seen in 16.7 to 32% of AD 
patients as seen using MRI (78, 79, 155, 156, 297).  When using positron emission 
tomography (PET) with amyloid labeling 11C-Pittsburgh Compound B (PiB), 
microhemorrhages usually occur in regions that have concentrated amyloid 
deposits of individuals with and without AD (99). 
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CHAPTER TWO: β-Amyloid 
APP and APP Processing 
The Aβ peptide is a cleavage product of the amyloid precursor protein (APP) 
(152, 153).  The Aβ peptide was first sequenced from amyloid deposits in 
meningio-cerebral blood vessels of a patient with Down’s syndrome (DS) and AD 
(137, 140). Subsequently, APP was localized to chromosome 21 (209, 343, 433).  
APP is a single transmembrane polypeptide glycoprotein whose function is 
unknown (476).  APP is commonly cleaved between residues 16 and 17 of the Aβ 
region by α-secretase resulting in a soluble ectodomain region (APPs-α) and its 
release into vesicle lumens.  Alternatively, APP can be cleaved by β-secretase 
cutting APP to release a truncated form of soluble APP (APPs-β), which is also 
released into the vesicle lumen (393). Cleavage by either α-secretase or β-
secretase also results in a carboxy terminal fragment (CTF) still within the 
membrane that will ultimately be cleaved by γ-secretase resulting in either the 
peptide p3 (if first cleaved by α-secretases) or Aβ peptide (if first cleaved by β-
secretase) (464, 500).  The majority of APP undergoes processing by α- and γ-
secretases while less undergoes the amyloidogenic processing by β-secretase 
and γ-secretase (387).  Various mutations in APP or PSEN1 or PSEN2 genes, as 
described in the genetic risk factors of AD section of Chapter 1, can lead to 
increased amyloidogenic processing of APP.  Genetic mutations identified in the 
APP or PS gene causing AD in addition to the observation that older individuals 
with trisomy 21 DS having an earlier onset of AD and faster progression of the 
disease led to the amyloid hypothesis (141, 158, 179, 295, 309).  The amyloid 
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hypothesis proposes that production of Aβ and its intracellular deposition in 
neurons along with extracellular formation of diffuse and neuritic plaques is the 
initiating factor resulting in tau hyperphosphorylation and activation of microglia,  
ultimately leading to neurodegeneration (119, 159). 
Aβ Peptide 
During the amyloidogenic processing of APP, γ-secretase can cleave the 
CTF at various sites leading to multiple isoforms of Aβ peptide ranging from 36 to 
43 amino acids long (74, 136, 194). The two most common isoforms of Aβ are Aβ1-
40 and Aβ1-42 which are 40 or 42 amino acids in length, respectively (74, 136, 194).  
While the biological function of Aβ peptide is not well known, it does have a 
hydrophobic structure that self-aggregates into dimers, trimers, tetramers, 
oligomers, and fibrils (262).  In general Aβ1-40 is more soluble, less toxic, and found 
in plaques, but more commonly associated with deposition in the blood vessels 
(324, 389, 498).  Aβ1-42 on the other hand is more hydrophobic making it more 
readily aggregated to form fibrils and plaques representing the majority of 
parenchymal Aβ (324, 389, 477).  Up to 90% of Aβ in the brains of individuals of 
AD can be of the Aβ42 species (144). Individuals with familial AD due to APP 
mutations will have increased levels of extracellular Aβ1-42 or both Aβ1-40 and Aβ1-
42 depending on the mutation (61, 68, 427), while PSEN1 or PSEN2 mutations 
selectively increase Aβ1-42 levels (382). 
Soluble and Insoluble Aβ 
The various forms of Aβ can be either soluble or insoluble.  The soluble 
form of Aβ can be found in CSF, plasma, and serum as well as in brain tissue (262, 
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390).  Soluble CSF Aβ1-40 and Aβ1-42 can be used as biomarkers to predict AD 
pathology progression in the brain (153, 394, 398).  CSF Aβ1-42 is reduced in 
individuals with AD and inversely proportional to the level of cognitive impairment 
and Aβ pathology in the brain of that individual (13, 128). Generally, those without 
AD have higher levels of CSF Aβ and lower levels of brain Aβ.  Lower CSF Aβ 
would indicate the movement of Aβ from the periphery into the brain (13, 128).  
While CSF Aβ levels inversely correlate with AD pathology in the brain and 
cognitive decline, Plasma Aβ1-40 and Aβ1-42 levels are more variable and less 
reliable as a biomarker of AD (268, 272, 463).  Additionally, the levels of Aβ1-40 and 
Aβ1-42 are much higher and more easily measured in CSF than plasma Aβ1-40 and 
Aβ1-42 levels (268, 272, 463).  The insoluble form of Aβ can only be found in tissue 
(294, 473).  Insoluble Aβ is generally fibrous in nature and makes up a large 
proportion of Aβ plaques (262).  The Aβ that forms plaque cores is generally more 
insoluble than that from vascular deposits (262).  While both soluble and insoluble 
Aβ correlate with cognitive impairment, soluble Aβ levels measured by biochemical 
assays appear to better correlate  with cognition than insoluble dense plaque 
deposition measured immunohistochemically (252, 271, 396). 
Aβ Oligomers 
Aβ is also very toxic in its soluble oligomeric form (252, 271).  When Aβ 
monomers assemble with one another they can form soluble oligomers which can 
exist in multiple forms such as dimers, trimers, or Aβ*56 (a dodecameric Aβ 
formation) (235).  Two studies in the early 1990’s demonstrated a poor correlation 
between fibrillar Aβ and cognitive decline in patients with AD (98, 442).  Later 
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soluble non-fibrillar Aβ levels were shown to have a strong correlation with AD 
(252, 271).  With these studies it was suggested that soluble Aβ may be a greater 
contributor to progression of AD than the previously thought deposited fibrillar Aβ 
(252, 271).  Since Aβ oligomers provide more surface area for interaction with 
neural synapses than plaques, they are thought to be more synaptotoxic.  
Oligomers modulate both pre- and post-synaptic structure and functions in a dose 
dependent manner (313, 388).  This synaptotoxicity by oligomers causes inhibition 
of long term potentiation in the hippocampus contributing to cognitive decline 
(470). 
Aβ Plaques 
Aβ is deposited extracellularly and aggregates into plaques (389).  As 
mentioned, Aβ is self-aggregating and first forms polymers that then create beta 
pleated sheet formations making up Aβ fibrils (389).  The insoluble Aβ fibrils may 
be inactive but are reservoirs of smaller Aβ assemblies (153, 294, 394, 398).  
These fibrils can then become cytotoxic when misfolded leading to amyloidosis 
and aggregating to form Aβ plaques (389).  Both Aβ1-40 and Aβ1-42 can be found in 
plaques, but since Aβ1-42 is more fibrillogenic of the two it is observed in Aβ plaques 
earlier in the disease (145, 193).  Two types of plaques can form, diffuse and dense 
plaques.  Diffuse plaques are primarily made of Aβ1-42, while dense plaques 
contain both Aβ1-40 and Aβ1-42 (263).  When stained by immunohistochemistry, 
diffuse plaques have a cloud like structure while dense plaques are more globular.   
 
 
 
21 
Post-translationally modified Aβ 
Aside from the multiple Aβ isoforms that can result in the c-terminal 
cleavage by γ-secretase, there can also be N-terminal heterogeneity (429).  This 
heterogeneity leads to various shorter peptides including Aβ5-40, Aβ5-42, Aβ3-40, and 
Aβ3-42 (65, 429). Additional post-translational modifications can occur with these N-
truncated Aβ peptides.  For example, an amino terminal modification can occur in 
which there is a proteolytic removal of residues 1 and 2 (Asp and Ala) (287). 
Another type of post-translational modification that can occur is the cyclizing of 
residue 3 or 11 of Aβ (Glu) to a pyroglutamate (pE) by glutaminyl cyclase (QC) 
(287, 384).  The most prominent forms of the pEAβ species are Aβ3(pE)-40, Aβ3(pE)-
42, Aβ11(pE)-40, and Aβ11(pE)-42 (365).  As stated earlier, up to 90% of Aβ in the brain 
ends in Aβ42 (144).  Truncated and modified Aβ make up most of the Aβ42 in the 
brain with Aβ3(pE)-42 being the most prevalent form (144, 428).  The prevalence of 
N-truncated and modified Aβ peptides is even greater in the brains of patients with 
familial AD compared to those with sporadic AD suggesting that post-
translationally modified Aβ has a decisive role in  the development of AD (282, 
361). pEAβ is more readily aggregated, more toxic, and is resistant to degradation 
(8, 162, 362, 383, 385, 487).  Schilling et al. studied the seeding and 
oligomerization capacity of the pEAβ peptide species and found that formation of 
seeds required for forming fibrils was very rapid compared to unmodified Aβ 
peptide (383).  This suggests the pEAβ peptide species is more toxic and could 
initiate Aβ aggregation and plaque formation by unmodified Aβ (383).  Since pEAβ 
peptide species promotes the advancement of Aβ pathology early in AD, then this 
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species could be a marker of older Aβ deposits (383).  With the N-terminal 
pyroglutamyl present, pEAβ is resistant to N-terminal targeted degradation, adding 
to the toxicity of this Aβ peptide species (364).  These attributes suggest that the 
pEAβ species plays a prominent role in the overall progression of AD (162, 186, 
362, 383, 440) and may determine the severity of disease state in an individual 
(360). 
Not only is pEAβ involved with Aβ pathology in AD, but two recent studies 
indicate an involvement in hyperphosphorylated tau pathology (256, 305).  In 2012, 
Nussbaum et al. examined the connections between pEAβ and tau in AD, finding 
that the toxicity of pEAβ and tau were dependent on one another (305).  Later, 
Mandler et al in 2014 measured and compared pEAβ3, full-length Aβ, and 
hyperphosphorylated tau loads in the frontal cortex and entorhinal cortex of 41 post 
mortem brains of both individuals with AD and controls (256).  As expected, all 
loads were higher in AD.  Interestingly, when looking at pEAβ3-x independently of 
full-length Aβ, pEAβ3 predicted AD and hyperphosphorylated tau while full-length 
Aβ only predicted AD (256).  High levels of hyperphosphorylated tau came with 
greater loads of pEAβ3, but were not affected by the absence of full-length Aβ 
(256).  The greater toxicity, resistance to degradation, correlation with 
hyperphosphorylated tau and the progression of AD make pEAβ a critical peptide 
to evaluate in future AD studies and therapeutic development. 
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CHAPTER THREE: Dog Model 
Used previously published material with permission. 
Davis, P.R., Head, E. Prevention approaches in a preclinical canine model of 
Alzheimer’s disease: benefits and challenges. Front. Pharmacol. 2014: 5: 1-14 
 
The Canine Model of Human Aging and Alzheimer’s disease 
Some of the most commonly studied animal models of human brain aging 
are rodents and nonhuman primates (129).  Other animals, including wolves, 
bears, cats, and dogs, naturally develop human-like neuropathology (172).  Of 
these animals, cats and dogs tend to have similar living environments to humans 
(172). Canines, however, show cognitive decline with age and develop most 
aspects of neuropathology seen in aged human brain including AD patients (81, 
87).  Such neuropathology includes Aβ pathology, reduced brain volume, neuronal 
loss, and impaired neurogenesis (81, 163).  In addition to the similar cognitive 
decline and accumulation of neuropathological hallmarks to humans with AD, 
drugs exhibit similar pharmacokinetics when administered to dogs or humans (for 
example statins - (7, 132)), making them an appropriate model for translational 
studies on therapeutic drugs.  Not only are dogs easy to handle due to their long 
history of domestication, but pet dogs also share similar living conditions and diets 
to humans (30, 87, 316). Canines are highly motivated by food reward when 
conducting cognitive tests, which makes them cooperative research subjects by 
reducing or eliminating deprivation protocols for motivation.  Thus, this 
cooperativeness eliminates many physiological stressors that can affect cognitive 
testing results present in other animal models such as rodents that require food 
deprivation or cold water for motivation (40).  The similar cognitive decline and 
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accumulation of neuropathology to humans makes the canine model of aging 
useful for translational research on neurodegenerative diseases, especially AD. 
Cognitive Outcome Measures 
There are several measures of cognition that are age-sensitive and 
treatment-sensitive in dogs that can be used as intervention outcome measures to 
assess different cognitive abilities with analogous tasks in nonhuman primates and 
in humans.  Much like humans, the aging canine shows cognitive decline with 
various cognitive domains and cortical pathways being differentially affected (277).  
Dogs show cognitive deficits due to age in tests measuring complex learning, 
executive function, spatial learning and attention, and memory (67, 82, 166, 277, 
280, 410, 424, 434, 435, 437).  In addition to cognitive domain variability, individual 
dogs also show variability in cognitive function as seen in humans (3).  This 
variability becomes most apparent in old canines, and using spatial learning and 
memory tasks, three groups of animals can be identified: (1) successful agers, (2) 
impaired dogs whose scores fell 2 standard deviations above the mean of the 
young animals, and (3) severely impaired dogs who failed to learn the task (172).  
The availability of age-matched animals with and without cognitive deficits allowed 
researchers to determine which types of neuropathology contribute to individual 
cognitive impairments in these animals (e.g. (166)). 
Several tasks, similar to those used for testing cognition in non-human 
primates, have been developed to measure cognitive decline in the aging canine 
(274, 276, 277).  Such tasks include landmark discrimination, oddity discrimination, 
object, size and black / white discrimination and reversal tasks, and a spatial 
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memory task.  Cognitive testing  occur in a modified Wisconsin General Testing 
Apparatus such that the motor and sensory demands are consistent across tasks 
(277).  For each task, 10-12 trials are given per day and dogs are tested daily until 
a predetermined criterion level of performance is reached; total error scores are 
added up across days to provide a measure of learning and/or memory for each 
animal.  These tasks are described in more detail below to illustrate how a test 
battery can be developed to measure the function of several brain circuits that may 
be differentially affected by age and/or treatment in aging dogs. 
Landmark Discrimination Task 
The landmark discrimination task, which measures visuospatial function 
and allocentric learning, involves presenting dogs with two identical objects, one 
of which is adjacent to a third object that serves as a landmark (274).  Animals are 
required to recognize that the landmark is an indicator of which object covers the 
food reward, and selection of the object closest to this landmark by the animal is 
considered a correct response. The task is made successively more difficult by 
placing the landmark further away from the object covering the reward. Previous 
work shows that aged dogs are impaired on the landmark task and show age 
decrements in their ability to determine how close the landmark is to the correct 
object (274, 276). 
Oddity Discrimination Task 
The oddity discrimination task measures complex learning, as well as 
prefrontal cortex function (82).  Aged dogs show deficits in oddity discrimination 
learning (82, 280).  In this task, dogs are presented with three objects 
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simultaneously, two of which are identical and a third that is unique.  A correct 
response is indicated when the dog chooses the unique object, resulting in a 
reward.  To prevent a floor effect and detect progressive age decline, the oddity 
aspect of this task is made successively more difficult.  Animals progress through 
four sets of three objects and each subsequent set contains a unique object, which 
is more difficult to distinguish from others than the previous set (280). Interestingly, 
young dogs can solve this problem by using the strategy of selecting the novel 
object for each successive set of objects such that error scores plateau; in contrast, 
aged dogs do not learn a strategy but re-learn each set of objects as a new problem 
(82, 280). 
Object, Size and Black/White Discrimination 
Tests of object, size and black/white discrimination are administered to 
measure associative learning ability. Object discrimination involves presenting 
dogs with two different objects simultaneously with one of the two objects 
consistently rewarded. Dogs must learn to select the same object each 
presentation with the left/right position being randomly determined. Similarly, the 
size discrimination objects differ in size (small/large) and the black/white 
discrimination task objects differ only in color (black/white) (278).  Object, size and 
black/white discrimination are also progressively more difficult for animals to solve 
given the similarities in the objects increasing. Thus, these 3 tasks in combination 
can serve as different test versions (much like in clinical studies in people) to 
assess longitudinal changes in learning while reducing practice effects (278). 
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Object, Size or Black/White Reversal 
Executive function can be evaluated immediately after discrimination 
learning has been completed by using the object, size or black/white reversal 
tasks.  The reversal tasks differ from the original discrimination task in that the 
positive and negative objects for reward contingencies are reversed after animals 
have learned the initial discrimination (278, 279).  Reversing the reward 
contingencies can show perseverative behaviors (persistent choice of previously 
correct object), which are frontal cortex dependent (474). A subset of the 
discrimination learning tasks and all reversal learning tasks are age dependent, 
with reversal learning being consistently more impaired with age (277-279, 410, 
437). 
Spatial Memory Task 
Memory also declines with age in dogs.  The most useful age-sensitive task 
we have used is a spatial memory task, in which dogs are required to recognize 
the location of a sample stimulus and then respond to a different location during 
the test trial.  We refer to this as a delayed non-match to position task (DNMP) and 
it involves showing animals a single object covering a food reward either on the 
left or right food well. After animals move the object and obtain the reward, the 
object is withdrawn from sight for a predetermined delay period (e.g. 10s). 
Subsequently animals are given two identical objects to choose from; one is the 
same object in the same position as before and one is in a novel position. The 
correct response is to select the object covering the novel location.  Results 
published in 1995 (170) suggested that the task was age-sensitive. We 
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subsequently developed a 3-choice visuospatial working memory task that allows 
determination of the differential age-dependent strategies (e.g. cognitive or 
stimulus-dependent strategies) dogs use in solving the problem (66). In this task, 
rather than just the left and right food wells, a center well is also included to make 
the task more difficult.  Further, this task shows minimal practice effects in 
longitudinal studies (177). The time course of the development of cognitive decline 
was identified and deterioration in spatial ability occurs early in the aging process, 
between 6 and 7 years of age in dogs (424). 
Behavioral/Functional Outcome Measures 
In addition to cognitive outcome measures, researchers and veterinarians 
are interested in measuring functional outcomes.  Further, laboratory-based 
cognitive testing as described above is labor intensive and requires many months 
to years to obtain data. An open field test can be used to observe the behavioral 
patterns of animals in an empty room for 10 minutes. During this task, movement, 
sniffing, urinating, grooming, rearing, jumping, vocalization, and inactivity are 
noted (171, 409, 411).  Self-recognition can be evaluated through the mirror test, 
originally developed for primates (91, 130), by observing the reaction of each 
animal with a mirror and their reflection.  Exploratory behavior of canines can be 
assessed through a curiosity test in which animals are presented with various 
novel play objects.  During their time with the objects, the amount of time the dogs 
spend in physical contact with or sitting next to the objects is recorded as well as 
their frequency of sniffing the objects (411).  Social responsiveness of dogs can 
be gauged through a few different tasks: a human interaction test, silhouette test, 
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and the model dog test. A human interaction test is performed by the presence of 
a person in the middle of the room and recording the reaction of the dog to that 
person by measuring the time the dog is in physical contact with the person, time 
sitting or standing beside the person, and frequency sniffing the person (167).  The 
silhouette test records the animals frequency of sniffing the front and rear regions 
of a cardboard silhouette of a dog posted onto a wall (123). The model dog test 
also records the sniffing frequency of the dogs, but this time in response to the 
presence of a life size model dog in the center of a room (411). 
Behavioral patterns in these functional tasks show age effects as well as 
differential effects based on the presence of intact/impaired cognition.  In 2001, 
Siwak et al. characterized the behavioral profiles of young (2 to 4 years), aged (9-
15 years) cognitively impaired, and aged non-impaired beagles (411). Young dogs 
tend to show greater responsiveness to changes in environments such as the 
addition of novel objects and a person.  They also showed greater social 
responsiveness spending the most time next to or sniffing a person, silhouette, 
and model dog.  Aged unimpaired dogs were still responsive to alterations in 
environment, but to a lesser degree than the young animals.  Additionally, aged 
unimpaired dogs spent the least amount of time reacting to the mirror during the 
self-recognition task.  Unlike either the young or aged unimpaired canines, the 
aged impaired canines were unresponsive to all stimuli presented to the 
environment and randomly moved about the room in pacing/aimless behavior.  
However, the aged impaired dogs did spend the most time interacting with the 
mirror in the self-recognition test (411).   
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Measures of canine function can also be assessed in a clinical setting (231-
233). Clinical measures have been developed consisting of pet dog owner based 
evaluation of dog behavioral changes (46, 47, 72, 233, 330, 331) similar to those 
used in human clinical evaluations, such as the Mini Mental State Exam (MMSE). 
Although there are different versions of these questionnaires, all appear to be 
sensitive to the presence of canine cognitive dysfunction (233).  The evaluation 
consists of items such as walking, posture/emotion of expression, elimination 
behavior, life rhythm, play behavior, exploratory behavior, learned specific 
behavior, adaptive capabilities, and interactions with other animals or with owners.  
The items of individual questionnaires can be used to derive scores that distinguish 
between normally and pathologically aging dogs.  Adult and older dogs generally 
score worse with these types of evaluation tools, and old dogs show individual 
variability in terms of the amount of cognitive dysfunction reported (47). 
Dog Neuropathology and Outcome Measures 
Just as canines can exhibit cognitive decline with age similar to aging 
humans and patients with AD, several human-type neuropathologies have been 
reported in dogs (81). In particular, the canine model has long been suggested as 
an excellent model of Aβ pathogenesis (490). Several changes observed in the 
aged canine brain are associated with cognition and are discussed below. 
Brain Volume 
Individuals with AD show significant cortical and hippocampal atrophy and 
ventricular enlargement relative to non-demented age matched controls (6, 340) 
and losses in brain volume correlate with cognitive decline (105, 114). Similar 
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events are seen in aged canines.  On cross sectional MR imaging, aging canines 
show increased cortical atrophy and ventricular widening (143, 218, 425).  
Ventricular widening over time was observed by MRI in a 3-year longitudinal study 
(426).  Canine cortical atrophy occurs earliest in the prefrontal cortex and later with 
age in the hippocampus (436).  As with humans, the more extensive the 
cortical/hippocampal atrophy seen in aged canines the more pronounced the 
cognitive deficits (347, 436). 
Neuronal Loss 
There is some evidence for neuronal loss in AD that could account for brain 
volume losses seen in brain imaging (404, 478).  With normal brain aging, neuronal 
loss is only seen in the hilus (478, 479), while neuronal loss is much more 
widespread in individuals with AD (42, 480).  Individuals with AD experience 
neuronal loss in the CA1, CA2, CA4, dentate gyrus and subiculum of the 
hippocampus (42, 327, 480).  In aged beagles, the hilus of the dentate gyrus 
showed fewer neurons compared to younger dogs (408).  Beagles with fewer 
neurons in the hilus made significantly more errors when performing the size 
discrimination task (408).  Similarly, Pugliese et al. found that a loss of Purkinje 
cells of the cerebellum in canines correlated with data acquired by questionnaires 
quantifying behavioral deficits (330).  However, neuronal loss may not account for 
all of the brain atrophy observed by MR as the loss of neuronal dendritic spines 
occurs with AD (221, 312) but to our knowledge, there are currently no studies 
published evaluating similar changes with age in dogs. 
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Neurogenesis 
While selective neuronal loss may occur with aging, the brain is also able 
to produce new neurons.  The hippocampus, for example, grows new neurons in 
the subgranular layer (111), as described in Chapter 1.  Neurogenesis has been 
explored in aged beagles using BrdU and doublecortin staining methods.  Siwak-
Tapp et al. measured neurogenesis in aged beagles using BrdU and found that 
animals over the age of 13 showed a significant loss of neurogenesis (407).  Fewer 
newer BrdU positive neurons was associated with poorer cognitive function in 
learning and memory (407). 
Β-Amyloid 
Beta-amyloid (Aβ) is derived from a longer precursor protein, the amyloid 
precursor protein (APP). The APP sequence of Canis familiaris has 98% homology 
with human APP (http://www.ensembl.org/Canis_familiaris/) and an identical 
amino acid sequence (207, 391).  Additionally, dog Aβ peptides may undergo the 
same posttranslational modifications as in humans (31, 371). These similarities 
make canines a viable aging model without the need for genetic modification or 
overexpression of mutant human proteins (391).   
The Aβ present in canines is ultrastructurally fibrillar and, though more 
compact deposits may form, it generally aggregates into diffuse plaques (88, 133, 
293, 359, 454, 455, 458). This type of Aβ deposition most resembles early AD 
pathology (81, 257, 288) (Figure 3.1A).  Since most AD therapeutics studied today 
are likely to have a greater affect if applied earlier in the disease progression, the 
early AD-like pathology canines produce makes them an attractive model for 
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preclinical prevention studies (258).  As with cognitive decline, AD-like 
neuropathology has a region specific progression in both humans and canines (52, 
133, 168, 391, 445, 488).  Though this progression in dogs is similar to that 
reported in humans, it is not identical.  In canines, the accumulation of Aβ begins 
in the prefrontal cortex (approximately 8 years at age of onset) and continues to 
develop with increasing age to include other regions such as the temporal and 
occipital cortex (81, 168, 358).  The severity of neuropathology can vary between 
individual animals but can be linked to the extent of cognitive decline (72, 86, 169, 
347).  For instance, animals who perform worse in reversal learning tasks have 
greater Aβ pathology in the prefrontal cortex, while those deficient in size 
discrimination learning show higher amounts of Aβ in the entorhinal cortex (86, 
166, 322). 
Aβ peptide can also be measured in the cerebrospinal fluid (CSF) of dogs 
(370).  Measuring CSF Aβ as a ratio of Aβ42/ Aβ40 is a good predictor of Aβ in the 
brain in dogs (176).  While brain Aβ increases with age, CSF Aβ decreases with 
age reflecting the hypothesis that Aβ migrates from the periphery and deposits in 
the brain with age and AD.   
Aside from the fibrillar Aβ found in diffuse plaques in AD, a smaller, more 
soluble form of Aβ, oligomeric Aβ, - is also seen in the aged dog brain.  This more 
toxic form of Aβ affects synaptic function and can be found in plaques (213, 390, 
471).  Higher levels of oligomers are present in canines and humans with 
increasing age and cognitive decline. The greater the cognitive deficit, the more 
prevalent oligomers are in the brain (321, 453).  Similar to fibrillar Aβ, oligomeric 
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Aβ can be measured in CSF, where levels are inversely related to levels in the 
brain (176). 
Cerebrovascular Pathology 
Aβ can also aggregate in the cerebral blood vessel walls and cause 
cerebrovascular pathology (27, 180, 328).  This type of deposition is referred to as 
cerebral amyloid angiopathy (CAA) (Figure 3.1B, C, D).  Typically CAA is 
composed of the shorter Aβ 1-40 peptide (27, 180, 491).  Both humans and 
canines exhibit CAA pathology, with a particular vulnerability in the occipital cortex 
(28).  CAA impairs the blood brain barrier, vascular function, and can cause 
microhemorrhages and occasionally hemorrhagic strokes (92, 328, 456).  Because 
of these complications, CAA may contribute to cognitive decline in both humans 
(27, 109, 302, 342) and canines (133, 164, 456, 457).  Much like humans, canines 
develop microhemorrhages with age (457) (Figure 3.1E).  These cerebral 
hemorrhages are present in both animals with and without CAA, but are more 
common in those with the blood vessel pathology (457). Given the significant 
overlap of cerebrovascular pathology with AD, the spontaneous accumulation of 
CAA in dogs also offers as yet, an underappreciated model system to test the 
effects of cerebrovascular pathology on cognition and AD neuropathology. 
Neurofibrillary Tangles 
One hallmark AD pathology canines do not produce is NFTs (359, 391).  
While no research to date has observed NFTs in the canine brain, the increased 
phosphorylation seen at some sites of tau in AD cases also occurs in cognitively 
impaired canines (173, 230, 315, 332, 475).  This lack of NFT pathology could 
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possibly be due to significant differences in the tau protein sequence between 
canines and humans (http://www.ensembl.org/Canis_familiaris/).  However, an 
advantage to dogs not accumulating NFTs is that they serve as a model that is 
selective for Aβ pathology and ideally suited for testing interventions that target 
this toxic protein. 
Treatment Studies in Aged Dogs 
Several studies have investigated therapeutic strategies using the canine 
model of aging and AD with both cognitive and neuropathological outcome 
measures (Table 3.1). 
Antioxidant-rich Diet in Combination with Behavioral Enrichment 
One of the earliest studies to develop a treatment for cognitive dysfunction in 
aged dogs tested an antioxidant-rich diet in combination with behavioral 
enrichment in aged dogs.  The rationale for this study was observations of 
increased oxidative damage in the canine brain (346, 347, 413) and studies in 
mouse models of AD showing environmental enrichment benefited cognition and 
reduced Aβ pathology (17, 202, 239). The diet included vitamins E and C, fruits 
and vegetables, lipoic acid and carnitine.  The behavioral enrichment included 
increased exercise, interaction with other dogs, and cognitive enrichment (82, 276, 
278, 279).  Compared to control animals, those receiving an antioxidant-rich diet 
committed fewer errors during landmark acquisition and retention tasks (276) as 
well as oddity discrimination tasks (82). Treatment with an antioxidant diet and 
behavioral enrichment resulted in improved performance during black and white 
object discrimination and reversal (278).  Pop and colleagues found dogs provided 
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with both behavioral enrichment and an antioxidant diet have an overall reduction 
in Aβ pathology across multiple regions of the brain (322) However, when looking 
at group treatment effects, only the antioxidant-treated animals had a significant 
reduction in Aβ plaque pathology.  Additionally, the combination treatment 
approach of behavioral enrichment and an antioxidant-rich diet in aged canines 
was unable to reduce existing brain Aβ, but was able to slow the accumulation of 
Aβ (322). While plaque load was affected by the combined intervention, soluble 
and insoluble Aβ1-40 was not reduced, and only soluble levels of Aβ1-42 were 
lowered specifically in the prefrontal cortex. A trend towards a significant decrease 
in oligomers, specifically in the parietal cortex, was observed in canines receiving 
the combined treatment (322).  Interestingly, the combination group also showed 
reduced oxidative damage (310) with the antioxidant diet group alone showing 
reduced mitochondrial dysfunction (175). Further, the behavioral enrichment 
group, independent of the antioxidant diet treatment showed less neuron loss in 
the hippocampus (408) as well as improved levels of brain derived neurotrophic 
factor  (115).  
Supplemental Medium-Chain TAG 
Supplemental medium-chain TAG (MCT) increases ketone levels in the 
brain, and these ketones can in turn be used as an alternative energy source. In 
2010, Pan and colleagues measured cognitive effects of this supplement on the 
landmark discrimination, oddity discrimination, and 2 choice egocentric spatial 
learning tasks.  Results indicated aged dogs given a diet with MCT 
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supplementation performed better than those receiving a control diet in all tasks 
(314). 
Medical Food Cocktail 
In contrast, fewer benefits on cognition were observed in a study using a 
medical food cocktail (174).  Dogs receiving a combination cocktail containing an 
extract of turmeric containing 95% curcuminoids, an extract of green tea containing 
50% epigallocatechingallate, N-acetyl cysteine, R-alpha lipoic acid and an extract 
of black pepper containing 95% piperine exhibited fewer errors compared to 
control animals during the landmark task indicating improved spatial attention.  
However, other areas of cognition were unaffected and brain Aβ remained 
unchanged (174). 
Cholesterol-lowering Drugs 
Several studies in the aged dog have tested the effects of drugs already 
approved for use in humans, with novel applications to brain aging. For example, 
several cross-sectional or case-control epidemiological studies revealed a striking 
link between cholesterol-lowering drugs (e.g. statins and others) and a 20-70% 
reduction in risk of developing AD (108, 154, 204, 344, 345, 492, 493, 503).  
Modest cognitive benefits have been reported in preliminary AD clinical trials with 
simvastatin (406) and atorvastatin (416-419).  In particular, AD patients with mild 
to moderate dementia who were treated with 80 mg/day atorvastatin had 
significantly improved scores on one measure of cognition (ADAS-Cog) at 6 
months of treatment, with smaller non-significant benefits at 12 months (419). 
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Statins may reduce the risk of incident AD through the prevention of Aβ 
production (160, 405).  In rodent models, treatment with inhibitors of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) or statins reduces Aβ (319). However, 
rodents respond to statin treatment by massively upregulating HMG-CoA 
reductase levels (7, 118, 446, 452).  To compensate, long-term studies in rodent 
often employ physiologically excessive doses, making it difficult to translate the 
results of these studies into human trials.  
The dog model is particularly useful to study chronic statin treatment, given 
similarities with humans in terms of dose requirements, responsiveness, drug 
handling, and metabolism (7, 132). For example, 12 dogs were treated with 80 
mg/day of atorvastatin for 14.5 months (296). Peripheral levels of cholesterol, low 
density lipoproteins, triglycerides and high density lipoproteins were reduced in 
treated dogs. Surprisingly, a transient impairment in reversal learning was 
observed, suggesting prefrontal dysfunction. Spatial memory remained 
unchanged up to over a year of treatment. The lack of cognitive benefits of 
treatment was also reflected by a lack of reduction in plasma, CSF, and brain Aβ.  
Interestingly, BACE1 protein level was decreased in the brains of atorvastatin-
treated dogs. This intriguing outcome may suggest that statins might be more 
useful to prevent the production of Aβ through lowering BACE1 if started in animals 
in middle age, consistent with human studies indicating that middle-aged 
individuals using statins are protected from AD. 
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Immunotherapy 
In 2008, a therapeutic approach that directly targeted Aβ reduction was 
explored in which aged beagles were actively immunized with fibrillar Aβ1-42 for 2 
years (VAC) based upon previous work in transgenic mouse models of AD (381).  
Schenk and colleagues were one of the first groups to explore the immunotherapy 
approach and found that active immunization with fibrillar Aβ1-42 reduced Aβ 
pathology in aged mice while preventing accumulation in young mice (381).  
Additionally, behavioral outcomes improved in treated mice (198, 286).  When 
testing this immunotherapy approach in a larger animal model, the aging caning, 
results showed no improvement in cognitive function, but interestingly a long term 
maintenance of executive function was noted based on error scores from the size 
reversal learning task (177).  However, significant benefits to brain pathology were 
observed in the VAC dogs who showed significantly decreased Aβ plaque load in 
prefrontal, entorhinal, and occipital cortical regions, as well as reduced CAA (177). 
While soluble and insoluble brain Aβ1-40 and Aβ1-42 significantly decreased in 
treated canines, there was no significant reduction in soluble oligomers. This study 
suggests that reducing or eliminating pre-existing Aβ in aging dogs is not sufficient 
to improve cognition.  
Outcomes from the longitudinal dog active vaccination study are similar to 
reports of Aβ immunotherapy clinical trials in patients with AD where no differences 
between antibody responders and placebo groups on several cognitive and 
disability scales was observed. A small number of patients enrolled in the AN1792 
study have come to autopsy and show A plaque reduction without any effect on 
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the extent of neurofibrillary tangles or CAA (120, 259, 301).  Further, the frontal 
cortex showed the largest response to immunotherapy (259), which is similar to 
our observations in the dog.  The most recent autopsy study of 8 patients that were 
in the AN1792 study further confirm reduced Aβ pathology in response to 
treatment, 5 years after the last injection (182).  However, reduction of brain Aβ 
did not slow disease progression and 7 of 8 patients had severe end stage 
dementia prior to death. (134).  Interestingly, a composite score of a 
neuropsychological test battery  indicated “less worsening” of decline in antibody 
responders after 12 months and an improvement in the memory domain (134). 
In contrast, Bosch et al. recently (2013) showed benefits of an active fibrillar 
Aβ40 and Aβx-40 combination vaccine on cognition in aged companion beagles and 
pet dogs treated for 51 days   (46).  Over the course of treatment, cognitive 
evaluations by questionnaire were given at 31 days post treatment and at the end 
of treatment.  Immunized animals showed a significant improvement in cognitive 
evaluation scores at both 31 and 51 days post treatment compared to pre-
immunized scores (46). Differences in the formulation, the outcome measures or 
the source of animals may explain the positive effects in the Bosch study compared 
with the previous beagle immunotherapy studies. 
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Table 3.1. Treatment Studies in Aging Dogs
Treatment Sample 
size and 
Age 
Landmark 
Discrim. 
Oddity 
Discrim. 
Size 
Discrim. 
Size 
Reversal 
Black White 
Discrim. 
Black/white 
Reversal 
Spatial 
Memory 
Question
-naire 
Publication 
Antioxidant diet 
28 old 
(8-13 
yrs) 
Improved Improved Improved Improved Improved Improved Improved N/A (82, 278, 279) 
Behavioral 
Enrichment 
N/A N/A Improved Improved Improved Improved Improved N/A 
Antioxidant Diet 
+ Behavioral 
Enrichment 
Improved Improved Improved Improved Improved Improved Improved N/A 
MCT Dietary 
supplement 
24 old 
(9-10 
yrs) 
Not 
Improv. 
Impaired N/A N/A N/A N/A Impaired N/A (314) 
Medical Food 
Cocktail 
18 old 
(8-9 yrs) 
Improved Not 
Improv. 
Not Improv. Not Improv. Not Improv. Not Improv. Not 
Improv. 
N/A (174) 
Atorvastatin 10 old 
(9-13 
yrs) 
N/A N/A Not Improv. Impaired Not Improv. Not Improv. Not 
Improv. 
N/A (296) 
Fibrillar Aβ1-42 
Immunotherapy 
20 old 
(8-13 
yrs) 
Not 
Improv. 
Not 
Improv. 
Not Improv. Maintained Not Improv. Maintained Not 
Improv. 
N/A (177) 
Fibrillar Aβ 1-40 
& x-40 
Immunotherapy 
12 old 
(11-18 
yrs) 
N/A N/A N/A N/A N/A N/A N/A Improved (46) 
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Figure 3.1.  Aβ Pathology in an Aged Beagle.  
The prefrontal cortex of a 13.8 year old beagle immunostained with Aβ 1-16 (6E10) 
showing Aβ deposition.  Arrows indicate intact neurons within diffuse plaques (A).  
CAA clustering in the prefrontal cortex of a 12.7 year old beagle immunostained 
with Aβ 1-16 (6E10) (B).  Cross section of a blood vessel with CAA in the prefrontal 
cortex of a 14.5 year old beagle immunostained with Aβ 1-16 (6E10) (C).  CAA 
shown in a longitudinal blood vessel of a 13.7 year old beagle (occipital cortex) 
stained with Congo red (C).  Note the striations of CAA along the blood vessel wall 
indicated by arrows (C). Microhemorrhages are seen by Prussian blue staining in 
the prefrontal cortex of a 13.8 year old beagle (E).  The arrow points to a cross 
section of a blood vessel with a microhemorrhage and the arrowhead indicates a 
hemosiderin laden perivascular microglia (E). 
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CHAPTER FOUR: Significance and Rationale 
Introduction 
5.1 million people in the United States are affected by Alzheimer’s disease 
(AD), the most common form of dementia, with no current treatment available  
(495).  As described in Chapter 1 (Alzheimer’s Disease), the hallmark lesions of 
AD include neurofibrillary tangles (NFTs), and plaques made up of the β-amyloid 
protein (Aβ) that result from cleavage of the amyloid precursor protein (APP) (255, 
389). While there is no cure for AD, there are various approved drugs for use as 
symptomatic treatments of AD.  Three of these drugs are acetylcholinesterase 
inhibitors, donepezil, rivastigmine, and galantamine, and a noncompetitive NMDA-
receptor antagonist, memantine (124, 131).  These drugs only act to manage the 
symptoms of AD for a limited period of time until the symptoms are too great and 
the drugs become ineffective.  In addition, no current biomarker can determine 
when AD pathology will occur or how it will progress in an individual, resulting in a 
variable age of onset of disease.   An individual may be clinically normal while their 
brain may have sufficient pathology for an AD diagnosis (85).  For those reasons, 
researchers have spent the past several years developing numerous therapeutic 
strategies to specifically reduce neuropathology and improve cognition in AD 
patients (392) 
An exciting therapeutic strategy being evaluated is immunotherapy 
(immunization or vaccination).  Specifically, several immunotherapies being 
explored target the reduction of Aβ.  This approach aims to reduce Aβ 
accumulation and increase its clearance in AD patients with the goal of reversing 
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cognitive decline due to the AD neuropathology.  Both active and passive Aβ 
immunotherapies have been explored by researchers. 
Aβ Immunotherapy as a Therapeutic for AD 
Active vaccination involves the administration of a vaccine containing an 
antigen to induce the recipient’s immune response that produces antibodies 
against that antigen.  The benefit of this type of vaccine is that only a small number 
of vaccinations are required to promote an immune response to produce 
antibodies and maintain that response.  However, the disadvantage is the 
variability in immune response between patients.  Passive immunotherapy 
involves the delivery of antibodies against the antigen of interest derived from a 
source other than the recipient.  The benefit to this type of immunization is the 
ability to administer the desired amount of therapeutic antibodies.  The 
disadvantage is that passive immunization requires repeated injections or 
infusions in order to maintain the desired antibody concentration in the recipient 
over time (43, 44, 234).   
The mechanism by which immunotherapy works is still unclear, however 
there are several hypotheses.  Only about 0.1% of antibodies in the periphery are 
able to pass into the brain (43, 44, 203, 234).  Although a majority of antibodies do 
not pass into the brain, the volume of anti-amyloid antibodies in the periphery can 
cause a “peripheral sink” effect driving the movement of Aβ out of the brain and 
into the periphery (43, 44, 203, 234).  This “peripheral sink” hypothesis has been 
demonstrated in multiple animal models (94).  Of the antibodies that do reach the 
brain, several possible mechanisms could contribute to the reduction of Aβ levels 
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and pathology.  For one, the anti-Aβ antibodies could bind to soluble forms of Aβ 
increasing their clearance or causing a shift of equilibria leading to insoluble Aβ 
breaking down into a more soluble form (234).  Antibodies could be binding to Aβ 
plaques promoting microglial activation to aid in clearing out plaques (34, 43, 45, 
301).  Additionally, bound Aβ to antibodies may disrupt its ability to aggregate into 
plaques (234). 
Active vaccination with the Aβ peptide was first described by Schenk and 
colleagues (381).  A study of transgenic mice vaccinated with the Aβ peptide 
demonstrated that not only was Aβ accumulation reduced in older animals with 
pre-existing Aβ pathology, but it was prevented in younger mice (prior to Aβ 
pathology) as well.  In addition, behavioral outcomes were improved (198, 286).  
As a result, the study progressed to a clinical trial in which mild to moderate AD 
patients were immunized with fibrillar Aβ1-42 with QS-2 in polysorbate 80 as an 
adjuvant (181).  Promising initial data showed 20% of the AD patients developed 
antibodies to fibrillar Aβ and had improved brain function (181).  However, in a 
second larger clinical trial in 2005, while some patients developed antibodies and 
had reduced Aβ plaques, no cognitive improvement was seen, and the trial was 
ultimately halted when a subset of patients developed aseptic meningoencephalitis 
(135).  Some of the patients who had developed meningoencephalitis possessed 
an elevated t-cell response in the brain.  This T-cell response is thought to be 
associated with the adjuvant used in the vaccine, QS-2 in polysorbate 80 (135). 
Subsequently, a second generation of immunotherapy, passive 
immunotherapy, has been developed.  In 2010, there were 15 passive Aβ 
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immunotherapies in clinical trials including bapineuzumab and solanezumab (241).  
These two passive immunotherapies, like active immunotherapy, aim to remove 
preexisting Aβ pathology and reduce cognitive decline.     
Bapineuzumab is a humanized monoclonal antibody to Aβ1-5. In mice, this 
antibody reduced Aβ pathology (94, 438).  In Phase III clinical trials, bapineuzumab 
may have reduced Aβ accumulation and phosphorylated tau levels as seen in 
cases that reached autopsy. However, the treatment failed to improve cognition in 
patients with and without the ApoE4 allele, a gene that associated with an 
increased risk of developing AD (341, 366, 367, 403).  It was suggested that the 
dosage of bapineuzumab used in the Phase III trials was too low to reach the 
desired primary outcomes (366, 367), however Phase II trials using greater doses 
resulted in more cases of edema and microhemorrhages in treated patients (368, 
420).  The doses used in Phase III trials showed no significant adverse effects due 
to bapineuzumab treatment (366, 367). 
Solanezumab, another humanized monoclonal antibody, targets Aβ16-24, and 
reverses memory impairment in the PDAPP mouse model of AD (32, 94, 100, 438).  
However, solanezumab immunotherapy leads to variable effects on Aβ burden 
including both reduction (94) or no change (100).  Solanezumab subsequently was 
tested in two Phase III clinical trials, but both trials failed to meet prespecified 
primary outcomes of improving cognition and function (101, 102).  While primary 
outcome measures were not met, a reduced rate of cognitive decline seen in 
patients with mild AD was observed in one study (101, 102).  Additionally, no 
significant adverse effects are seen due to the solanezumab treatment (101, 102, 
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401).  Further studies will continue to explore solanezumab in patients with mild 
AD or those who   lack the clinical symptoms of AD but show brain Aβ accumulation 
through biomarker measures (101, 102).  
Although the passive immunotherapy approach was thought to be safer and 
more promising than active vaccination since no adjuvant is needed, 
bapineuzumab and solanezumab both failed to meet efficacy expectations and 
fulfil primary outcomes of reducing or slowing down cognitive decline in AD 
patients (101, 102, 341, 366, 367, 401, 403).  Additionally, there are still concerns 
with adverse effects such as edema and intracerebral microhemorrhages (60, 320, 
368, 420, 483). Thus, there is a critical need to continue to refine and develop 
novel therapeutics for AD.  Two possible reasons for negative clinical trials 
outcomes are (1) the preclinical animal model was not a predictor of human clinical 
trial outcomes and (2) the serious adverse events were harmful to the patients due 
to the immunotherapies themselves. 
Aβ Immunotherapy in the Canine Model of AD 
In Chapter 3 we describe a unique animal model, the canine, which shows 
similar neuropathology and cognitive decline to humans with AD.  Canines 
naturally produce APP that has 98% homology with human APP, develop Aβ 
neuropathology, and show cognitive decline with age, similar to AD patients (253, 
277, 475, 501).  The similar neuropathology and cognitive decline coupled with 
their common living conditions with humans make dogs useful for translational 
studies on neurodegenerative diseases such as AD. 
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The active vaccine used in this study differs from past clinically tested active 
vaccines in that it uses Aluminum hydroxide (Alum) as an adjuvant in place of the 
QS-2 in polysorbate 80.  This Alum adjuvant is commonly used in other active 
vaccines that can be safely administered in humans and causes minimal, if any, 
T-cell responses in the brain.  As discussed in Chapter 3,in a study reported in 
2008, aged beagles were actively immunized with fibrillar Aβ1-42 using Alum as 
an adjuvant (VAC) for 2 years (177). In addition, VAC dogs had significantly 
decreased Aβ plaque load (177).  No serious adverse events such as those 
reported in the previously described human clinical trials were reported. However, 
Aβ immunotherapy in aging dogs with preexisting pathology led to no improvement 
in cognitive function, but interestingly a long term maintenance of executive 
function that was noted based on error scores from the size reversal learning task 
(177). These results suggest that reducing Aβ alone was insufficient to improve 
cognition but that over time, lower levels of brain Aβ can support cognitive 
maintenance. 
Behavioral Enrichment in the Canine Model of AD 
Another therapeutic strategy being explored is behavioral enrichment.  
Behavioral enrichment (ENR) includes environmental enrichment, exercise, social 
engagement, and cognitive enrichment.  Though a combined ENR approach has 
not been explored in other animal models, individual aspects of ENR have been 
studied.  In rodents, exercise leads to increased brain derived neurotropic factor 
and improved learning (80).  However, the effects of ENR on transgenic mouse 
models of AD have shown significant variability between studies (17, 202, 239). In 
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people, individuals who live behaviorally enriched lifestyles, which includes 
exercising or participation in activities that involve information processing, tend to 
show less brain atrophy with age and exhibit reduced risk of dementia (70, 71, 
485).  
As discussed in Chapter 3, behavioral enrichment (ENR) in the canine model 
of aging has been evaluated.  In a study of aged canines, ENR included increased 
exercise, interaction with other dogs, and cognitive enrichment.  In 2004 and 2005, 
Milgram and colleagues found ENR of aged canines to decrease the rate of 
cognitive decline and improve cognitive function (278, 279).  
A Combination Approach to Improve Cognition and Reduce Pathology in the 
Canine Model of AD 
Immunotherapy decreases Aβ pathology in humans and AD animal models, 
while ENR improves overall cognition, growth factor levels and supporting neuron 
number with varying Aβ outcomes.(116, 278, 279, 407).  These results suggest 
the exploration of a combination treatment approach with the potential for additive 
effects to improve brain function and health with age.  This study evaluates the 
combination approach of active Aβ vaccination and behavioral enrichment by 
examining their effects on cognition and neuropathology.  We hypothesize that 
additive benefits of improved cognition with reduced AD like pathology will be 
exhibited in treated aged canines receiving a combination treatment approach of 
active immunization with fibrillar Aβ1-42 using aluminum hydroxide (ALUM) as an 
adjuvant (VAC) with ENR. 
Copyright © Paulina R. Davis 2014  
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CHAPTER FIVE: Methodology 
Canines 
The study was started with 40 beagles with 37 animals from the Lovelace 
Respiratory Research Institute (LRRI) (Albuquerque, NM) and 3 from Harlan 
(Riglan Farms, Inc., Mount Horeb, Wisconsin) (Table 5.1).  All animals were 
reproductively intact. At the start of baseline, the ages of the dogs ranged from 
10.5 to 13.6 years.  At this age range, all study animals should have significant 
prefrontal Aβ pathology (168).  Animals were housed singly in kennel buildings 
with indoor/outdoor runs measuring 91cm x 600cm, unless otherwise noted as part 
of the ENR treatment. Animals were fed Harlan Teklad Global Diet (25% protein – 
Teklad Pioneer Lab Diets, Madison, WI) once daily.  Water was available for the 
animals at all times.  All animals were given a thorough veterinary examination to 
assure they were in good health before inclusion in the study.  Examinations 
included physical examination, neurological examination, and analysis of blood 
biochemistry.  All procedures done with the animals were conducted in accordance 
with LRRI-approved animal protocols and the National Institutes of Health Policy 
on Humane Care and Use of Laboratory Animals.   
Testing Apparatus 
As described previously (277), the testing apparatus was a 0.609 X 1.15 X 
1.08 m wooden box constructed from press board coated with melamine.  The box 
contained a sliding black Plexiglas tray containing three food wells. Adjustable 
vertical stainless steel bars provided openings appropriate for individual dog sized 
and made up the front of the box.  The bottom of the barrier opened up so that a 
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sliding tray would be able to be pushed either toward or out-of-view of the dog. A 
60W light was placed above the presentation tray to light the objects.  Data 
acquisition was controlled by a customized program, DOGMA (MetaCog Testing 
Systems, New Westminster, BC).  This program controlled randomization 
procedures and timing, indicated the placement of the reward, and stored all of 
data.  Each trial began when an experimenter pressed a key and the program 
would provide an audio cue to present the tray to the dog.  The dog’s response 
would be recorded by identifying the location (left, right, or center) on the keyboard 
or by a mouse.  This also indicated the end of the trial and began an intertrial 
interval.  One teaspoon of wet dog food was formed into a ball and served as the 
food reward.  Each dog was given either 10 or 12 trials a day (depending on the 
task). The dogs were tested 5 day a week. 
Baseline Cognitive Testing 
All dogs underwent a series of baseline tests and error scores during this 
testing were used to counterbalance placement into treatment groups such that 
each group contained both good and poor performers.  All animals were given a 
reward and object approach learning task and then a simple object discrimination 
and reversal learning task.  After discrimination learning, dogs were given a spatial 
non-matching-to-position memory task.  All tasks were performed as described in 
Chapter 3, Dog Model. After placement into treatment groups, VAC and ENR 
protocols were started, and cognitive testing was conducted for 19 months while 
treatment was ongoing. 
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Treatment Groups 
The total errors made by each dog during baseline testing were summed and 
used to rank animals according to total error scores.  These cognitive test scored 
were used to place animals into one of four treatment groups, making sure that 
groups were balanced by baseline performance and age.  These treatment groups 
included (1) immunization with Alum only (n = 8) (C/C), (2) ENR with immunization 
with Alum only (n = 8) (E/C), (3) immunization with fibrillar Aβ1-42 and Alum (n = 8) 
(C/V), or (4) ENR with immunization with fibrillar Aβ1-42 and Alum (n = 10) (E/V) 
(Table 5.2). 
Behavioral Enrichment Procedure 
Dogs receiving ENR (groups E/C and B/V) were given a 20 min walk outdoors 
in groups of 3-4 animals three times a week.  Play toys were rotated through their 
kennels on a weekly basis.  ENR animals received cognitive enrichment involving 
additional testing procedures including: landmark discrimination learning, variable 
distance landmark discrimination, oddity discrimination learning and a second re-
test on landmark discrimination after ~16 months of treatment.  For these cognitive 
tasks, only dogs receiving ENR were included however we were able to compare 
VAC and non-VAC dogs on each measure (Table 5.3).   
Immunization Procedure   
Fibrillar Aβ (provided by Dr. Charles Glabe, University of California at Irvine) 
was prepared by adding 500 µl of phosphate buffer solution (PBS), pH 7.5, to 0.5 
mg of peptide, and the sample was vortexed and incubated overnight at 37°C in a 
water bath before formulation with the adjuvant.  To prepare Aβ for immunization, 
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0.5 mg of fibrillar Aβ (500 µl) was added to 50 µl of 2% aluminum hydroxide 
suspension (Accurate Chemical, Westbury, NY) and 450 µl of PBS and vortexed.  
Animals in the C/C and E/C groups received Alum only. Animals were immunized 
subcutaneously in the back of the neck and monitored for adverse reaction.  
Animals were boosted every month with an additional single injection for 18 
months. 
Treatment Cognitive Testing 
At predetermined time points during the study, animals were given tests to 
measure spatial attention (landmark discrimination learning), spatial memory 
(three-choice spatial testing), oddity learning, discrimination learning, and reversal 
learning (black/white discrimination and size discrimination) (Table 5.3).  All tasks 
were performed as described in Chapter 1, Dog Model. 
Serum and CSF Collection 
Blood samples were obtained at baseline, taken immediately before the first 
immunization to obtain a pre-immune sample, monthly for six months, and then 
every six months thereafter. Blood was collected in 10 cc collection tubes and 
centrifuged, and the supernatant (serum) used to assay anti-Aβ antibodies.   
Serum samples were thawed, aliquoted, and frozen again at -80°C for later use.  
Cerebral spinal fluid (CSF) was collect from each animal at the start of the study 
before the first immunization (baseline), 12 months after start of treatment, and at 
the time of euthanasia.  CSF was drawn from the lateral ventricles, aliquoted, 
frozen, and were stored at -80°C for later use. 
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Euthanasia and Tissue Collection 
At the end of the study, animals were anesthetized with sodium pentobarbital 
(Nembutal). Blood was collected in 10 cc red top tubes and centrifuged, and the 
supernatant (serum) used to assay anti-Aβ antibodies.  When animals were in 
deep surgical stage, the brains were rapidly removed. Procedures were performed 
in accordance with LRRI Institutional Animal Care and Use Committee protocols.  
The left hemisphere was placed in 4% paraformaldehyde at 4°C for48 hours before 
transfer to PBS, pH 7.4 with 0.02% sodium azide and stored at 4°C. The right 
hemisphere was coronally sectioned and stored at -80°C. 
Serum IgG ELISA 
Aβ1-42 antibody response was measured over nine time points of the study 
by enzyme-linked immunosorbent assay (ELISA). 96 well flat bottom plates 
(Microtiter Immunlon 2 HB, Fisher, cat# 14-245-61) were coated with 5µg/ml 
fibrillar Aβ1-42 in 0.1M phosphate buffered saline (PBS) (pH 7.5) and incubated 
overnight at 4°C.  Blank wells received PBS only. After incubation, plates were 
washed three times in Tris buffered saline with 0.05% Tween-20 (TBST) (pH 7.5). 
Plates were then blocked with blocking buffer (TBST with 3% bovine serum 
albumin (BSA)) and incubated for two hours at 37° on a plate rocker.  Plates that 
were not used immediately after blocking were stored at 4°C until needed.  Once 
blocked, plates were washed three times in TBST.  Serum samples being used 
were serially diluted in 1:10 dilution of blocking buffer (0.3% BSA in 2mM TBST) 
to 1:100, 1:400. 1:800, and 1:1600.  Antibody 6E10 (Aβ1-16, Covance, Dedham, 
MA; cat# SIG-39320) was used for standards and serially diluted to 1:10,000, 
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1:20,000, 1:40,000, 1:80,000, 1:160,000, and 1:320,000.  Wells received 100µl of 
each sample, 6E10 antibody, or PBS.  For a positive control and serum only control 
wells, 100 µl of 6E10 at 1:10,000 dilution and 1:200 dilution of sample was added, 
respectively.  Plates were incubated for one hour at 37°C on a plate rocker.  After 
three washes in TBST, 100 µl of horseradish peroxidase (HRP) conjugated 
secondary antibody diluted in blocking buffer was added to each well. Canine 
sample wells received anti-dog IgG-HRP (Bethyl Laboratories, Montgomery, TX; 
cat# A40-116P) as secondary, while standard and control wells received anti-
mouse IgG-HRP (Santa Cruz Biotechnology, Santa Cruz, CA; cat# SC-2005).   
Plates were incubated with secondary antibody for one hour at 37°C on a plate 
rocker.  Following three washes in TBST, 100µl of 1 Step Ultra 3, 3’,5,5’-
tetramethylbenzidine solution (TMB) (Thermo Scientific, cat# 34028) (room 
temperature) was added to each well to start the reaction. TMB reaction was held 
for 3 minutes and then stopped by adding 100µl of 1N sulfuric acid. After 5 minutes 
when reaction has completely stopped, plates were read at 450 nm using a 
Multiscan FC plate reader (Thermo Scientific). 
Frozen Tissue Extractions 
Frozen tissue underwent a basic three step serial extraction before being 
used to measure Aβ content.  Tissue first went through a phosphate buffered saline 
(PBS) extraction.  200mg of tissue was homogenized in 1 mL of 4° 1x PBS with 
complete protease inhibitor cocktail (PIC; with EDTA; Amresco, Solon, OH, cat# 
M222-1mL) (pH 7.4).  Homogenization was done using a polytron at maximum 
speed. Raw homogenate was added into 1.5 mL centrifuge tubes and centrifuged 
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at 20,000 x g for 30 minutes at 4°C.  Supernatant was collected and stored at -
80°C while the pellet was saved and used for the following extraction by sodium 
dodecyl sulfate (SDS).  Here, room temperature 2% SDS with PIC (in water) was 
added to the PBS pellets.  The total volume of 2% SDS added to the PBS pellet 
was determined by calculating 70% the volume of PBS raw homogenate.  Samples 
were sonicated with 10x 0.5 second pulses with an amplitude of 20% (Fisher sonic 
Dismembrator, Model 500).  Samples were centrifuged at the same conditions as 
stated earlier.  Supernatant was collected and stored while the pellet was used for 
the following Formic Acid extraction.  For the last extraction by formic acid, samples 
were diluted 1:40. First samples were diluted 1:20 in neutralization buffer (Tris 
Phosphate Buffer) followed by a 1:1 dilution in antigen capture (AC) buffer (0.02M 
sodium phosphate buffer (pH=7), 0.4M NaCl, 0.02 M EDTA, 0.4% Block Ace 
(Serotec, Raleigh, NC), 0.2% BSA, 0.05% CHAPS, and 0.05% NaN3). Add 4° 
equal volume of 70% formic acid as that of SDS added to the PBS pellets to the 
SDS pellets.  Samples were sonicated with 10x 0.5 second pulses with an 
amplitude of 20% and centrifuged at 20,000 x g for 30 minutes at 4°C.  The 
underlying aqueous layer was collected and stored at -80°C for later use. 
CSF and Brain Aβ ELISAs 
Beta-amyloid (1-40, 1-42, and total) was measured in CSF and tissue by sandwich 
ELISA.  Capture antibodies Ab42.5 (human sequence Aβ1-16) for Aβ1-40 capture, 
and 2.1.3 (end specific for Aβ1-42) were diluted to 10 µg/mL in PBS and added 
(50µL) to each well of a 384 well plate (Immulon, cat# 4HBX).  Any unused wells 
were filled with 50 µL of PBS.  Once loaded, plates were sealed with sealing tape 
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and incubated overnight at 4°C.  Plates were then emptied and rinsed with 1X 
PBS. To block the plates, 100µL of Synblock (Serotec, cat# BUFO34C) was added 
to each well, sealed and incubated for 2 hours at room temperature on a plate 
rocker.  Once blocked, plates were emptied and dried for two hours at room 
temperature.  Plates not used the same day could be sealed and stored at 4° in a 
dessicator for later use.  Before antigen capture, plates were washed twice in 1X 
PBS. Samples were then added (100µL) in triplicate and then plates were sealed 
and incubated overnight at 4°C.  Fluid from wells was discarded and washed twice 
with 1X PBS and 1X PBST.  Next, 100µL of biotinylated detection antibodies 
biotinylated 13.1.1 (end specific for Aβ1-40, and biotinylated 4G8 (human sequence 
Aβ17-24, Covance) diluted in detection buffer (DB) (0.02M sodium phosphate buffer 
(pH=7), 0.002% Thimerosal, 0.002M EDTA, 0.4M NaCl, and 1% BSA) was added 
to the plates, sealed, and incubated at room temperature for four to six hours.  
Following an incubation in detection antibody, plates were emptied, washed, and 
filled with 100µL of NeutrAvidin-horse radish peroxidase (Pierce Biotechnologies, 
Rockford, IL) diluted in DB.  After incubating for two hours at room temperature, 
solution was discarded and plates were washed several times.  For developing, a 
1:1 mixture of TMB developing solution (Kirkegaard and Perry Laboratories, 
Gaithersburg, MD) was made and added (100µL) to each well and allow to 
incubate for about five minutes.  Developing reaction was stopped by adding 
100µL of stop buffer (5.6% O-Phosphoric Acid) to the wells and then plates were 
read with a BioTek multiwell plate reader at λ450nm. Total levels of Aβ1-40 and Aβ1-
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42 were determined by calculating the sum of levels in each fraction (PBS, SDS, 
and FA). 
Plaque Load IHC 
Tissue was stained for Aβ plaques by using anti-Aβ1-42 (Invitrogen, Carlsbad, CA; 
cat# 44-344; 1:500), 6E10 (Covance, Dedham, MA; cat# SIG-39320; 1:1000), and 
PyroGlu3 (Novus Biological, Littleton, CO; cat# NBP1-44048; 1:500)  (Table 5.4) 
antibodies. Tissue was pre-treated in 90% formic acid for 4 min and washed in 
Tris-buffered saline (TBS) (pH 7.5).  Next, a 30 min treatment in 3% hydrogen 
peroxide and 10% methanol was done to block endogenous peroxidase activity.  
After two washes in TBS, sections were then washed in TBS with 0.1% Triton X-
100 (Sigma X-100) and blocked in TBS with 0.1% Triton X-100 and 2% Bovine 
serum albumin for 30 min to block non-specific sites.  Sections were then 
incubated with primary antibody overnight at room temperature.  Following the 
primary antibody the tissue was incubated in biotinylated secondary antibody for 
rabbit or mouse (Vectastain Elite ABC kit, Vector Laboratories, Burlingame, CA; 
cat# PK-6101 (rabbit), PK-6102 (mouse)).  After several washes sections were 
incubated for one hour in an avidin-biotin complex (Vectastain Elite ABC kit, Vector 
Laboratories, Burlingame, CA; cat# PK6101).  Detection was visualized with 3’-
diaminobenzidine and hydrogen peroxide (DAB, Vector Labs, Burlington, CA; cat# 
SK4100).  Sections were mounted on Superfrost/Plus slides (Labsco Scientific 
America, cat# LSA4951), left to dry, dehydrated, and coverslipped with 66m glass 
coverslips (Labsco Scientific America, cat# LS529J) using Depex mounting media 
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(Electron Microscopy Sciences, cat# 13515).  Appropriate controls included 
sections eliminating primary or secondary antibodies, and all were negative. 
Prussian Blue Staining 
Prussian blue staining was used to identify microhemorrhages in PFCTX, OCTX, 
and Hippo tissue for all study cases.  With this stain, only iron from hemosiderin 
containing microglia in the extracellular matrix is colorized (indicative of 
microhemorrhages).  Prior to staining, tissue was mounted onto Labsco 
Superfrost/Plus slides and air dried overnight.  Slides were rehydrated in distilled 
water for 30 seconds and then incubated in 2% potassium ferrocyanide with 2% 
6N concentrated HCl (made in distilled water) for 30 minutes.  After incubation, 
slides were rinsed twice in distilled water for five minutes each and then once in 
tap water for another five minutes.  Once rinsed, slides were incubated in filtered 
1% neutral red solution (J.T. Baker, cat# R746-03) (mixed overnight) for two 
minutes.  Tissue was rinsed three times in tap water for 1 minute each, and 
dehydrated by dipping slides four times in 95% ethanol and four times in 100% 
ethanol.  Slides were cleared twice in xylene for five minutes each and then 
coverslipped with Depex mounting media. 
Baseline Comparison for Plaque Load and Prussian Blue 
We were interested in estimating the extent of Aβ pathology and 
microhemorrhages in our dogs prior to the start of treatment to characterize 
changes in pathology over time and with immunotherapy/behavioral enrichment. 
We selected 10 archive cases (Table 5.5) that ranged in age from 10.8 to 13.5 
years to compare changes in plaque loads and number of microhemorrhages 
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before treatment to after 19 months of treatment, particularly with ENR study 
animals.  These archive cases had no previous treatment or cognitive testing done.  
Tissue for archive cases were collected using the same methods as the study 
cases.   
Immunohistochemistry was used to measure total Aβ, Aβ1-42, and PyroGlu3 plaque 
loads in the PFCTX and PCTX and was conducted in the same manner as with 
study case tissue.  Prussian Blue staining was used to count the number of 
microhemorrhages in the PFCT and OCTX regions of the brain and was done in 
the same manner as with study case tissue.   
Image Analysis for Plaque Load and Prussian Blue 
To quantify the extent of Aβ plaque labeling, images were captured using 
ImagePro 6.3 with an Olympus Q-Color 5 camera on an Olympus BX51 
microscope at 20x objective uniformly, five of the superficial layers and five of the 
deep layer.  Quantification was done by image analysis using ImageJ to yield load 
values, the percent area occupied by positive labeling (Figure 5.1).  A threshold 
was identified for each antibody/marker and applied to calculate a total average 
load of each image.  The loads of all 10 images were averaged for each subject. 
These subject averages were then used to find a treatment group average for 
treatment group comparisons. 
Quantification of Prussian blue staining entailed manually counting 
microhemorrhages in each tissue sample at 20X objective.  Prussian blue labeling 
must have been within 2 cell diameters of a blood vessel to be considered a 
microhemorrhage (Figure 5.2).  Counts were totaled for each subject in each brain 
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region. For each brain region subject averages were used to calculate a treatment 
group average to be used for treatment group comparisons. 
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Table 5.1. Dogs used in the Study 
 
Dog ID Sex Date of Birth 
Baseline 
Date 
Age at 
Baseline (mo) 
Date of 
Death 
Age at 
Death 
(mo) 
       
1625A M 9/16/1997 4/18/2010 151.1 9/20/2010 156.2 
1625C M 9/16/1997 4/18/2010 151.1 7/23/2010 154.3 
1628A M 1/3/1998 4/18/2010 147.6 6/20/2012 173.7 
1628C M 1/3/1998 4/18/2010 147.6 6/18/2012 173.6 
1633D M 4/27/1998 4/18/2010 143.8 4/26/2012 168.1 
1633S F 4/27/1998 4/18/2010 143.8 6/20/2012 169.9 
1635A M 6/9/1998 4/18/2010 142.4 7/23/2010 145.5 
1635S F 6/9/1998 4/18/2010 142.4 2/26/2012 164.7 
1635T F 9/8/1998 4/18/2010 142.4 4/11/2012 166.2 
1636V F 6/28/1998 4/18/2010 141.8 6/7/2011 155.4 
1637B M 8/21/1998 4/18/2010 140.7 6/18/2012 166.8 
1637T F 7/29/1998 4/18/2010 140.7 6/19/2012 166.8 
1638U F 8/20/1998 4/18/2010 140 9/2/2010 144.5 
1639B M 8/21/1998 4/18/2010 140 6/19/2012 166.1 
1639C M 8/21/1998 4/18/2010 140 6/18/2012 166 
1639T F 8/21/1998 4/18/2010 140 6/18/2012 166 
1639W F 8/20/1998 4/18/2010 140 6/19/2012 166.1 
1640B M 9/8/1998 4/18/2010 139.4 6/19/2012 165.5 
1640C M 9/8/1998 4/18/2010 139.4 6/19/2012 165.5 
1640S F 9/8/1998 4/18/2010 139.4 5/17/2012 164.4 
1640U F 9/8/1998 4/18/2010 139.4 8/26/2011 155.7 
1640V F 9/8/1998 4/18/2010 139.4 4/18/2011 151.4 
1640W F 9/12/1998 4/18/2010 139.4 5/11/2012 164.2 
1641A M 9/12/1998 4/18/2010 139.3 6/20/2012 165.4 
1641B M 9/12/1998 4/18/2010 139.3 6/18/2012 165.3 
1641T F 9/12/1998 4/18/2010 139.3 8/22/2010 143.4 
1641U F 9/8/1998 4/18/2010 139.3 4/15/2011 151.2 
1641V F 9/12/1998 4/18/2010 139.3 6/18/2012 165.3 
1642A M 7/24/1999 4/18/2010 128.9 6/20/2012 155 
1642B M 7/24/1999 4/18/2010 128.9 6/20/2012 155 
1642S F 7/24/1999 4/18/2010 128.9 12/29/2011 149.3 
1643C M 7/24/1999 4/18/2010 128.9 7/2/2010 131.4 
1643T F 7/26/1999 4/18/2010 128.8 6/20/2012 154.9 
1645A M 8/10/1999 4/18/2010 128.4 6/20/2012 154.5 
1645T F 8/10/1999 4/18/2010 128.4 6/19/2012 154.4 
1646T F 10/16/1999 4/18/2010 126.1 6/18/2012 152.2 
1646U F 10/16/1999 4/18/2010 126.1 6/18/2012 152.2 
D009 M 12/8/1996 4/18/2010 160.4 7/9/2011 175.1 
D012 F 11/12/1996 4/18/2010 161.3 6/19/2012 187.3 
D045 F 9/15/1996 4/18/2010 163.2 6/19/2012 189.2 
  
64 
Table 5.2. Treatment Group Assignments 
 
 
 
 
 
  
Dog ID Treatment Group Time on Treatment (mo) 
   
1625A -- 0 
1625C -- 0 
1628A C/C 19.6 
1628C C/C 19.5 
1633D E/V 17.8 
1633S E/C 19.6 
1635A -- 0 
1635S E/V 15.8 
1635T C/V 17.3 
1636V E/V 7.1 
1637B C/V 19.5 
1637T E/C 19.6 
1638U -- 0 
1639B E/V 19.6 
1639C C/V 19.5 
1639T C/C 19.5 
1639W C/C 19.6 
1640B E/V 19.6 
1640C C/C 19.6 
1640S C/V 18.5 
1640U E/C 9.8 
1640V E/C 5.5 
1640W C/C 18.3 
1641A E/C 19.6 
1641B E/C 19.5 
1641T -- 0 
1641U E/C 5.4 
1641V C/C 19.5 
1642A C/V 19.6 
1642B E/V 19.6 
1642S C/V 13.9 
1643C -- 0 
1643T C/V 19.6 
1645A E/V 19.6 
1645T E/V 19.6 
1646T E/V 19.5 
1646U C/C 19.5 
D009 E/C 8.2 
D012 C/V 19.6 
D045 E/V 19.6 
  
65 
Table 5.3. Cognitive Testing Timeline 
Study Event 
Time 
Between 
Boosts 
Study 
Month 
Baseline 
Serum and Plasma Time B1   -6.0 
Blood Biochemistry - Time B1   -6.0 
Physical and Neurological Examinations Time B1   -6.0 
Pretraining - Phase 1   -6.0 
Reward Approach Learning   -6.2 
Pretraining - Phase 3   -6.2 
Object Approach learning   -6.0 
Baseline CSF sample     
Baseline - Object Discrimination Learning   -4.8 
Baseline - Object Reversal Learning   -4.6 
Baseline - 2 choice spatial learning   -4.0 
Baseline - 3 choice spatial learning   -3.7 
Baseline - 3 choice spatial memory   -1.1 
Blood Biochemistry - Time B2   -0.7 
Treatment 
Serum and Plasma Imm 0   0.7 
Immunization-1 0 0.7 
Begin behavioral enrichment protoocol   0.7 
Serum and Plasma Imm 2w   1.2 
Immunization-2 14 1.2 
Serum and Plasma Imm 1m   1.6 
Immunization 3 14 1.7 
Landmark Testing - Land0-Land4   1.7 
Serum and Plasma Imm 2m   2.6 
Immunization 4 28 2.6 
Serum and Plasma Imm 3m   3.5 
Immunization 5 28 3.5 
Oddity Discrimination Learning   4.2 
Serum and Plasma Imm 4m   4.5 
Immunization 6 28 4.5 
Serum and Plasma Imm 5m   5.4 
Immunization 7 28 5.4 
Physical and Neurological Examinations   6.1 
Serum and Plasma Imm 6m   6.3 
Immunization 8 28 6.3 
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Blood Biochemistry 6 m   6.3 
Immunization 9 28 7.3 
Immunization 10 28 8.2 
Time 1 - Size Discrimination Learning   8.4 
Time 1 - Size Reversal Learning   8.9 
Immunization 11 28 9.1 
Time 1 - Spatial Acquisition   10.0 
Immunization 12 28 10.1 
Immunization 13 28 11.0 
Immunization 14 28 11.9 
Blood Biochemistry 12m   11.9 
Physical and Neurological Examinations   11.9 
Serum and Plasma Imm 12m   11.9 
CSF sample   12.1 
Time 1 - Spatial Memory   12.4 
Immunization 15 28 12.9 
Immunization 16 28 13.8 
Immunization 17 28 14.7 
Immunization 18 28 15.7 
Time 2 - Landmark Variable Distance Retest   16.1 
Immunization 19 28 16.6 
Time 2 - Black/White Discrimination Learning   17.0 
Immunization 20 28 17.5 
Blood Biochemistry 18m   17.5 
Serum and Plasma Imm 18m   17.5 
Time 2 - Black/White Reversal Learning   17.7 
Physical and Neurological Examinations    18.2 
Immunization 21 28 18.5 
Time 2 - Spatial Memory   19.1 
Immunization 22 28 19.4 
BrdU injections once daily for 5 days   20.1 
Immunization 23 28 20.3 
Serum and Plasma Imm 23m   20.5 
Blood Biochemistry 24m   20.5 
CSF sample immediately prior to euthanasia   20.5 
Euthanasia   20.5 
 
 
 
 
Table 5.3, continued 
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Table 5.4. Antibodies used for Immunohistochemistry 
Antibody Name Target Dilution Secondary Manufacturer 
     
Aβ 1-42 Aβ (42) 1:500 Rabbit Invitrogen 
6E10 Aβ (1-16) 1:1000 Mouse Covance 
PyroGlu3 Aβ (3 pE) 1:500 Mouse Novus Biological 
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Table 5.5. Pre-Treatment Dogs used in the study 
Dog ID Sex Date of Birth Date of Death Age at Death (mo) 
     
1425S F 11/26/1983 6/3/1997 162.4 
1470S F 1/22/1986 6/11/1997 136.7 
1485V F 12/1/1986 4/1/1999 148.1 
1509S F 3/2/1988 12/18/1998 129.6 
1580S F 5/15/1991 12/11/2002 139.0 
1634U F 6/7/1998 1/29/2010 139.9 
1634V F 6/7/1998 4/7/2009 130.1 
1639U F 8/21/1998 4/6/2010 139.6 
1639V F 8/21/1998 2/17/2010 138.0 
D304 F 7/30/1991 12/23/2002 136.9 
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Figure 5.1. Quantification of Aβ Plaque loads.  
Black and white image taken of 6E10 labeled tissue (A) and the same capture 
that has been thresholded so that only positive labeling is seen in black (B).  This 
threshold is used to obtain a measure of total area occupied by positive labeling 
for 6E10. 
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Figure 5.2. MHs in the FCTX of AD and aged canine.  
Aged canines show MHs just as seen in aged humans. Arrows point to MHs 
in FCTX tissue stained with Prussian Blue of a human with AD (A) and of an aged 
canine PFCTX (B).  Arrowheads point to blood vessel associated with each 
neighboring MH.  Bleed labeling must have been within 2 cell diameters of a blood 
vessel to be considered a microhemorrhage. 
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CHAPTER SIX: Results 
Cognitive Outcomes 
Landmark Discrimination Learning 
All dogs receiving ENR were given the landmark discrimination task. Thus, a 
comparison between dogs receiving the vaccine could be compared to those not 
receiving the vaccine, with all dogs being behaviorally enriched.  Testing began 1 
month after the first vaccination and 2 weeks after the first boost.  
In the 18 (n=10 E/V, n=8 C/V) dogs that completed landmark 0, a significantly 
higher error score was observed in the dogs provided with the vaccine relative to 
the dogs receiving behavioral enrichment alone (t(16)=2.7 p=0.016)(Figure 6.1).  
However, based on our previous research, rather than the vaccinated dogs doing 
more poorly, this effect is due to significantly lower error scores in all dogs that was 
pronounced in the E/C group  when compared to previous studies of similarly aged 
dogs (276).  In landmark 1 discrimination learning, no significant group effects were 
observed (t(16)=1.45 p=0.17). Interestingly, in landmark 1 learning, two of the 
vaccinated dogs made over 100 errors to learn the task whereas the average error 
scores for the E/C condition was 9.88+/-4.74 and for the remaining dogs on E/V 
condition averaging 5.0 +/- 1.46 errors. Scores of over 100 errors are typical of 
untreated aged animals as previously reported (275, 276).  A differential vaccine 
effect was also not observed for landmark 2 (2 cm distance) (t(14)<1 p=0.77) or 
landmark 4 (4 cm distance) (t(14)<1 p=0.48). A similar outcome was noted if a 
repeated measures general linear models approach is used to detect differential 
effects of the vaccine across all landmark tasks although the effect of distance on 
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error scores overall was significant (F(3,42)=2.8 p=0.05) suggesting the further 
distances resulted in higher error scores reflecting increasing difficulty of the task 
(Figure 6.1).  
The variable distance landmark test was conducted for a period of 20 days 
with either 1,  2 or 4 cm distances appearing each day, four times/day for a total of 
12 trials/day.  The total number of errors made during the 20 days of testing was 
not different between the E/V nor E/C groups (t(13)<1 p=0.53).  Next, the accuracy 
was calculated for individual distances for each dog as further distances are more 
difficult for animals to detect proximity to the correct response.  All dogs performed 
between 62-72% correct with little variability across distances. A repeated 
measures general linear models analysis confirmed a lack of main effect of 
distance (F(2,24)=2.2 p=0.133) and of treatment group (F(1,12)<1 p=0.53).  The 
interaction, was also not significant (F1,12)< 1 p=0.78) (Figure 6.2).  This is 
contrast to previous reports of the variable distance landmark task varying as a 
function of distance (177). 
After 15.2 months of treatment, 4 E/C and 8 E/V dogs were given a second 
assessment of the landmark variable distance task for 240 trials.  There was a 
significant effect of distance of the landmark and error scores such that longer 
distances led to greater numbers of errors (F(2,20)=12.90 p=<.0005).  There were 
no differences between the group receiving the vaccine (E/V) and the control group 
(E/C) or an interaction between distance and treatment condition (data not shown). 
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Oddity Discrimination Learning 
A comparison was made between the 8 vaccinated (E/V) vs 10 non-
vaccinated (E/C) dogs on the oddity task after 4.3 months of treatment with all dogs 
having behavioral enrichment.  When individual oddity problems were analyzed 
using t-tests to compare the two groups we did not see any significant differences. 
For oddity 1, 7 E/C dogs and 9 E/V dogs reached criterion levels of responding 
(t(14)<1 p=n.s.).  For oddity 2, 7 E/C dogs and 9 E/V dogs learned the task 
(t(14)=1.40 p=0.18).  For oddity 3, 6 E/C dogs and 9 E/V dogs learned but no 
significant differences were observed (t(13)<1 p=n.s.).  Last, for oddity 4, 6 E/C 
dogs and 9 E/V dogs learned but error scores were similar (t(13)=1.37 p=0.20).  In 
a second repeated measures analysis (4 oddity tasks) using only dogs that were 
able to reach criterion levels of responding on all tasks, the two groups (E/C vs 
E/V) were compared. There was a significant main effect of the oddity task 
(3,39)=4.75 p=0.006) suggesting increasing difficulty, but no treatment group by 
oddity task interaction (F(3,39)=0.39 p=0.76).  Overall there were no treatment 
group differences (F(1,13)=3.41 p=0.088)(data not shown). 
Discrimination and Reversal Learning 
After 7.6 months of treatment, all dogs were given a size discrimination and 
reversal learning problem.  This task allowed us to compare all 4 treatment groups 
and test the hypothesis that the combined treatment led to greater cognitive 
benefits than either treatment alone and as compared to controls.  All dogs still on 
study learned the size discrimination problem.  Using a univariate analysis of 
variance (behavioral enrichment, vaccine), there was no significant effect of the 
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vaccine alone (F(1,30)<1 p=n.s.), the behavioral enrichment alone (F(1,30)=0.36 
p=0.55) nor the interaction of the two treatments (F(1,30)<1 p=n.s.).   For size 
reversal learning, 28 dogs in total learned the task.  No significant improvements 
in the vaccine group alone (F(1,28)=0.33 p=0.57), the behavioral enrichment group 
alone (F(1,28)=0.98 p=0.33) nor in the combination group (F(1,30)=0.029 p=0.87) 
was observed (data not shown).   
We next compared baseline levels of discrimination and reversal learning to 
size discrimination learning to determine if there was a maintenance of function in 
treated animals. In this repeated measures analysis, we observed a significant 
effect of time (or of task difficulty) between baseline discrimination learning and 
size discrimination learning (F(1,26)=10.74 p=0.003) with error scores being 
higher on the size task.  No group differences nor a group by time interaction was 
observed suggesting no treatment effects on the maintenance of discrimination 
learning (data not shown). Similarly for reversal learning, there was a significant 
effect of time (or of task difficulty) overall (F(1,24)=17.1 p<.0005) with size reversal 
leading to higher error scores but no main effects of each treatment nor a time by 
group interaction (data not shown).  
After 16.1 months of treatment, all dogs on the study were given the final 
discrimination learning and reversal tasks, black/white discrimination and 
black/white reversal learning. On the black/white discrimination learning task, 7 
C/C, 4 E/C, 3 C/V and 7 E/V animals were able to reach criterion. There was no 
main effect of the vaccine (F(1,21) = 1.49 p=0.24), the behavioral enrichment 
(F(1,21)=0.07 p=0.80) nor a significant combination treatment effect (F(1,21)=0.12 
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p=0.73) (data not shown).  Similarly, of the 6 C/C, 4 E/C, 3 C/V and 6 E/V dogs 
able to reach criterion on the black/white reversal learning task, no main effect of 
the vaccine (F(1,19)=0.32 p=0.58), of the behavioral enrichment (F(1,19)=0.79 
p=0.40) nor of the combination treatment (F(1,19)=3.26 p=0.09) was observed 
(data not shown). 
To detect any treatment effects over time (i.e. a possible maintenance of 
function) we compared baseline object discrimination to size discrimination and to 
black/white discrimination only in animals able to reach criterion for all 3 tasks. 
Overall there was a significant increase in error scores over time in all groups 
(F(2,32)=3.4 p=0.05) suggesting both an aging effect and an increase in task 
difficulty but no effect of the vaccine (F(2,32)=0.11 p=0.90) or of the behavioral 
enrichment alone (F(2, 32) =0.56 p=0.58). Interestingly, there was a significant 
effect of the combination treatment group (F(2, 32)=4.0 p=0.03) and as can be 
seen in Figure 6.3A, the combination group had the lowest average error scores. 
Reversal learning also showed a significant main effect of time in dogs that could 
learn the problem (F(2,30)=10.7 p<.0005) but there were no main effects of the 
vaccine alone (F(2,30)=2.8 p=0.08) or the behavioral enrichment alone 
(F(2,30)=0.09 p=0.91) nor of the combination treatment (F(2,30)=1.12 p=0.34) on 
change in error scores over time (Figure 6.3B).  Interestingly, as can be seen in 
Figure 6.3B, the E/V group had the highest average error scores on reversal 
learning, whereas the two single treatment groups showed lower error scores. 
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Spatial Acquisition and Memory 
Once dogs had been treated for 9.4 months, they were retested on the 3 
choice spatial memory problems. At this time, dogs were given 50 days maximum 
to sequentially re-acquire the task at progressively increasing delays beginning 
with a 5 second delay.  A multivariate analysis of variance was used to determine 
whether group differences were present with the initial re-learning at a 5 second 
delay.  In this analysis, 7 C/C dogs, 4 E/C dogs, 7 C/V dogs and 7 E/V dogs 
reached criterion levels of responding. No significant main effects of the vaccine 
(F(1,25)=0.577 p=0.46), of behavioral enrichment (F(1,25)=1.83 p=0.19) nor of the 
combined treatment (F(12,25)=0.039 p=0.85) was observed (data not shown).   
At the end of spatial acquisition testing, dogs were given a variable spatial 
memory task where the delays of 20, 70 or 110 seconds could occur on a single 
day. On this phase of the test, 8 C/C, 4 E/C, 8 C/V and 8 E/V dogs completed all 
240 trials.  The main effect of the delay interval on accuracy was marginally 
significant (F(2,48)=2.91 p=0.06) but no delay by vaccine group (F(2,48)=0.71 
p=0.50), no delay by behavioral enrichment group (F(2,48)=1.11 p=0.34) nor a 
delay by vaccine group by behavioral group interaction (F(2,48)=1.26 p=0.29) was 
found.  Thus, neither treatment alone or in combination resulted in improved spatial 
memory (Figure 6.4A and B).  
A third and final test of spatial memory alone (without the acquisition phase) 
was initiated after 18.1 months of treatment. For this test, 8 C/C, 4 E/C, 5 C/V and 
6 E/V dogs remained on study.  The overall effect of delay on accuracy was blunted 
in this last test (F(2,38)=2.85 p=.07) most likely due to the smaller sample size. 
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There was no delay by vaccine group effect (F(2,38)=0.72 p=0.49) or delay by 
behavioral enrichment group effect (F(2,38)=0.31 p=0.74). Interestingly, there was 
an interaction between the delay interval accuracy in the combination treatment 
group (F(2,38)=3.62 p=0.04). Figure 6.4C shows that this was primarily due to the 
poorer performance of the E/C and C/V groups at the short 20 second delay 
whereas the C/C and E/V groups showed a progressive decline in accuracy from 
20 to 110 seconds delays. 
To detect any changes in spatial memory as a function of treatment over the 
18 months of the study, a repeated measures analysis was used for each delay 
interval separately (20,70,110s).  At the 20 second delay (F(2,36)=16.12 p<.0005), 
the 70 second delay (F(2,36)=5.51 p=0.008) and the 110 second delay 
(F(2,36)=17.32 p<.0005) there was an overall decrease in accuracy over time 
suggesting an aging effect. There was no apparent maintenance of spatial memory 
over time as a function of treatment (Figure 6.4 D, E, F). 
IgG Anti-fibrillar Aβ Antibody Response in Serum 
To determine if the anti-fibrillar Aβ given to VAC treated animals induced an 
immune response, we measured fibrillar Aβ1-42 antibody titers (Figure 6.5). Past 
active vaccine studies showed an increase in Aβ antibody titers in treated animals 
(177).  Therefore, we hypothesized the C/V and E/V groups would have an 
increase in Aβ antibody titers over time.  At baseline, there were low and variable 
levels of anti-Aβ titers in serum across dogs. Thus, to reduce individual variability 
of measurements due to baseline titers and to allow comparisons across groups 
over time, the difference between each time point measure of anti-Aβ titers from 
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baseline was calculated.  Similar to previous studies, fibrillar Aβ antibody titers 
significantly increased over time in VAC animals (F(1,19)=12.5 p=0.002) (Figure 
6.5A).  No main effect of behavioral enrichment was seen on antibody titers 
(F(1,19)=1.16 p=0.30).  Further, there was no interaction between the two 
treatments (F(1,19)=1.32 p=0.26).  While antibody titers in the combination 
treatment group did increase over time, as can be seen in Figure 6.5B, the 
maximum response did not reach that of the vaccine only group (Figure 6.5A). Post 
hoc tests show that at time 23 months the combination group had lower titers 
(p=0.018, LSD).  Additionally, the antibody titer response in the combination 
treatment group was delayed about 2 months (Figure 6.5A).    
CSF Aβ 
CSF Aβ levels are lower in AD compared with non-demented elderly controls 
as Aβ from the periphery deposits in the brain decreasing CSF Aβ and increasing 
brain Aβ and cognitive impairment (for review, see (14)). In animal studies, mice 
receiving passive immunization with antibodies against soluble Aβ experience an 
increase in CSF Aβ (100).  Additionally, dogs receiving active vaccination 
experienced a non-significant increase in CSF Aβ1-40 and decrease in Aβ1-42 (165). 
We hypothesized that CSF Aβ levels would be higher in the C/V and E/V treatment 
groups compared to the C/C and E/C groups as a result of the VAC.  CSF Aβ1-40 
and Aβ1-42 were measured by sandwich ELISA.  A significant increase in CSF Aβ1-
40 levels was seen in response to ENR (F(1,22)=5.76 p=0.03) (Figure 6.6A), while 
there was no effect of the vaccine (F(1,22)=0.41 p=0.53) (Figure 6.6B) or an 
interaction between the two treatments (F(1,22)=1.16 p=0.29) (Figure 6.7).  
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Though not significant, the E/V treatment group trended towards having the largest 
impact in increasing CSF Aβ1-40 compared to all other treatment groups (Figure 
6.7).   No treatment effect was seen for ENR (F(1,22)=0.38 p=0.54) alone for Aβ1-
42 (Figure 6.8A). VAC had no treatment effect in lowering or raising CSF Aβ1-42 
over time (F(1,22)=0.40 p=0.40), but VAC animals did have significantly higher 
levels than non-VAC animals at 12 months (F(1,22)=8.089 p=0.008) (Figure 6.8B).  
Last, there was also no interaction treatment effect on CSF Aβ1-42 for the two 
treatments over time (F(1,22)=0.06 p=0.81) (Figure 6.9). 
Aβ Plaque Load 
Based on the previous canine vaccine study indicating that Aβ plaque loads 
were decreased due to VAC, we hypothesized that animals from the C/V and E/V 
treatment groups would have decreased Aβ plaque loads compared to non VAC 
animals (177). We also hypothesized that the E/V group would have a greater 
reduction in plaque load than the C/V group as an effect of the combination 
treatment approach. To test this hypothesis we measured the extent of plaques 
containing Aβ1-42, total Aβ, and pyroglutamate Aβ in the PFCTX, OCTX, PCTX, 
and ECTX by immunohistochemistry. 
Aβ1-42 
Aβ1-42 plaque load was measured in the PFCTX, OCTX, PCTX, and ECTX in 
all animals and compared between treatments.  Plaque load was significantly 
decreased as a result of VAC (both C/V and E/V groups) in the PFCTX (F(1, 34)= 
33.04 p= <0.001), OCTX (F(1, 34)= 14.92 p= 0.001), and PCTX (F(1, 33)= 14.06 
p= 0.001), while no reduction was seen in the entorhinal cortex (ECTX) (F(1, 34)= 
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1.89 p= 0.39) (Figure 6.10).  Compared to the C/C group, the C/V group showed 
a significantly lower Aβ1-42 plaque load in the PFCTX (Bonferroni, p=<0.001), 
OCTX (Bonferroni, p=0.04), and PCTX (Bonferroni, p=0.02) (Figure 6.10). 
However there was no significant difference between the C/C and C/V groups 
when comparing plaque loads in the ECTX (Bonferroni, p=1.00) (Figure 6.10).  No 
significant reduction in Aβ1-42 plaque load was seen as an effect of ENR in the 
OCTX (F(1,34)=0.19 p=0.67), PCTX (F(1,33)=2.21 p=0.15), or ECTX 
(F(1,34)=0.754 p=0.39) (Figure 6.10). However, a reduction in the PFCTX due to 
ENR trended towards significance (F(1,34)=3.87 p=0.06) (Figure 6.10). Similarly, 
when looking at individual treatment groups, the E/C group had a significantly 
lower plaque load compared to the C/C group in the PFCTX (Bonferroni, p=0.02), 
while no difference was seen in the OCTX (Bonferroni, p=1.00), PCTX (Bonferroni, 
p=0.55), or ECTX (Bonferroni, p=1.00) (Figure 6.10).  No additive effects were 
seen between the VAC and ENR in reducing Aβ1-42 plaque load in the OCTX 
(F(1,34)=0.14 p=0.71), PCTX (F(1,33)=1.18 p=0.29), or ECTX (F(1,34)=0.18 
p=0.68) (Figure 6.10).  Statistically by two way ANOVA, there was a significant 
additive effect of VAC and ENR in decreasing Aβ1-42 plaque load in the PFCTX 
(F(1,34)=6.54 p=0.02), however by post hoc the E/V treatment group did not have 
a lower plaque load than the C/V group, (p=1.000).  In the presence of active 
vaccine, the ENR group provides no additional benefit. But, where there was no 
vaccine, the ENR treatment makes a difference such that Aβ1-42 plaque load is 
lower. In other words, there is no additional effect of behavioral enrichment on the 
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vaccine group, but in the absence of vaccine, ENR resulted in lower Aβ1-42 plaques 
compared to the C/C group. 
Total Aβ 
Total Aβ (6E10) plaque load was measured in the PFCTS, OCTX, PCTX, 
and ECTX in all animals.  A significant decrease in total Aβ plaques was seen due 
to VAC (both C/V and E/V groups) in all brain regions (PFCTX, F(1,34)= 52.91 p= 
<0.001; OCTX, F(1,34)= 13.65 p= 0.001; PCTX, F(1,33)= 10.70 p= 0.003; ECTX, 
(F(1, 34)= 6.60 p= 0.02) (Figure 6.11).  When comparing the C/V group to C/C 
animals, C/V dogs had lower plaque loads in the PFCTX, OCTX, and PCTX 
(Bonferroni: p=<0.005, p=0.05, p=0.01 respectively) (Figure 6.11).  ENR did not 
have an effect on the reduction of total Aβ plaque load in any of the examined 
regions (PFCTX, F(1,34)=2.95 p=0.10; OCTX, F(1,34)=0.34 p=0.57; PCTX, 
F(1,33)=2.82 p=0.10; ECTX, F(1,34)=.23 p=0.64) (Figure 6.11).  Though there was 
no overall effect due to ENR, the E/V group did have lower total Aβ plaque loads 
compared to the C/C group in the PFCTX, OCTX, and PCTX (Bonferroni: 
p=<0.001; p=0.05; p=0.01 respectively) (Figure 6.11).  No additive effects were 
seen between VAC and ENR in decreasing total Aβ plaque loads from any of the 
PFCTX (F(1,34)=1.78 p=0.19), OCTX (F(1,34)=0.13 p=0.73), PCTX (F(1,33)=3.26 
p=0.08), or ECTX  (F(1,34)=0.03 p=0.86) (Figure 6.11).  The combination group, 
E/V, did however have decreased total Aβ plaque loads compared to controls, C/C 
(Figure 6.11).  Decreased total Aβ plaque loads was seen in the PFCTX 
(p=<0.001), OCTX (p=0.03), and PCTX (p=0.01) (Bonferroni) (Figure 6.11). 
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Pyroglutamate Modified Aβ 
Previous immunotherapy studies did not look into the effects of the 
treatment on post-translationally modified Aβ.  Since post translationally modified 
Aβ, more specifically AβpE3, is considered to be a more toxic and 
chronobiologically older form of Aβ, we tested our vaccine on its ability to reduce 
this form of Aβ.  Here we measured AβpE3 plaques loads in the PFCTX, OCTX, 
PCTX, and ECTX in all study animals.  We hypothesized that VAC would 
significantly reduce AβpE3 plaque loads in all regions examined and more so in 
the E/V treatment group dogs.  We found that VAC had a significant effect in 
decreasing AβpE3 plaques loads (Figure 6.12). AβpE3 plaque loads were 
decreased in PFCTX (F(1, 30)= 10.00 p= 0.004) and PCTX (F(1, 29)= 6.50 p= 
0.02), while no change was seen in the OCTX (F(1, 30)= 2.32 p= 0.14) or ECTX 
(F(1, 30)= 3.13 p= 0.09) (Figure 6.12).  The C/V group trended towards a 
significantly lower AβpE3 plaque load in the PCTX compared to that of the C/C 
group (Bonferroni, p=0.06) (Figure 6.12).  No reduction in plaque load was seen in 
any regions examined due to ENR (PFCXT, F(1,30)=0.09 p=0.77; OCTX, 
F(1,30)=0.84 p=0.37; PCTX, F(1,29)=1.30 p=0.26; ECTX, F(1,30)=1.59 p=0.22) 
and or the combination therapy approach (PFCXT, F(1,30)=0.05 p=0.83; OCTX, 
F(1,30)=1.32 p=0.26; PCTX, F(1,29)=2.33 p=0.14; ECTX, F(1,30)=2.65 p=0.11) 
(Figure 6.12). 
Comparison of Plaque Load Over Time Due to Treatments 
As mentioned, PFCTX had lower Aβ1-42 plaque loads as an effect of ENR 
that trended towards significance. In addition, though no ENR effect was 
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statistically seen in lowering total Aβ plaque loads in the PFCTX and PCTX, the 
E/C treatment group did have significantly lower loads than the C/C group.  What 
was unclear was if these lower plaque loads were due to a clearance of Aβ or 
maintenance of pre-existing pathology by the ENR.  In order to investigate this 
further, we used PFCTX and PCTX tissue of archive cases that were age matched 
to study cases at their baseline age and stained them for Aβ1-42 and total Aβ.  The 
results would provide measurements that would represent the Aβ1-42 and total Aβ 
plaque loads of the study cases at baseline before treatment began. 
In the PFCTX, a significant group effect was seen when comparing Aβ1-42 
(F(4, 44)= 9.447 p= <0.001) (Figure 6.13), total Aβ (F(4, 44)= 10.923 p= <0.001) 
(Figure 6.14), and AβpE3 (F(4, 44)= 9.752  p= 0.009) (Figure 6.15) plaque loads 
between the pre-treatment group to the study treatment groups.  The pre-treatment 
group had significantly lower Aβ1-42 (Bonferroni, p=0.050) (Figure 6.13) and total 
Aβ (Bonferroni, p=0.014) (Figure 6.14) plaque loads than the C/C group indicating 
that an increase in these plaque loads was seen with age.  The plaque loads of 
the pre-treatment group did not statistically differ from the E/C group, suggesting 
that a maintenance effect due to the ENR was likely in keeping Aβ Aβ1-42 
(Bonferroni, p=1.000 ) (Figure 6.13) and total Aβ (Bonferroni, p=1.000 ) (Figure 
6.14) plaque loads maintained compared to the C/C group (Figure 6.13).   Similar 
results were seen in the PCTX.  A significant group effect was seen when 
comparing Aβ1-42 (F(4, 44)=4.780  p=0.003) (Figure 6.13), total Aβ (F(4, 44)= 3.297 
p= 0.021) (Figure 6.14), and AβpE3 (F(4, 44)=3.321 p= 0.020) (Figure 6.15) plaque 
loads between the pre-treatment group to the study treatment groups in the PCTX.  
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Compared to the C/C group, the pre-treatment group had significantly lower Aβ1-
42 (Bonferroni, p=035) (Figure 6.13) indicating that an increase in plaque load was 
seen with age.  As seen in the PFCTX, the pre-treatment group Aβ1-42 plaque load 
did not differ significantly from the E/C group in the PCTX either, again suggesting 
a maintenance effect due to ENR was likely keeping Aβ1-42 plaque loads lower than 
the C/C group (Bonferroni, p=1.000 ) (Figure 6.13). 
Soluble and Insoluble Brain Aβ 
We hypothesized that the levels of soluble and insoluble Aβ in the brain would 
be reduced due to VAC and that the E/V treatment group would show an even 
greater reduction.  To test this hypothesis we measured PBS, SDS, and FA 
extracted Aβ1-40 and Aβ1-42 from the PFCTX, OCTX, PCTX and HIPPO regions of 
the brain by sandwich ELISA. 
Aβ1-42 
VAC significantly decreased Aβ1-42 in the PBS, SDS and FA extracts of the 
PFCTX (PBS, F(1, 34)= 2.518 p= 0.016; SDS, F(1, 34)=31.244  p= <0.005; FA, 
F(1, 34)=5.610  p= 0.024) and OCTX (PBS, F(1, 34)= 5.782 p= 0.023; SDS, F(1, 
34)= 14.451 p= 0.001; FA, F(1, 34)= 3.914 p= 0.057), while the PCTX and ECTX 
remained unchanged (Figure 6.13 A, C, E).  No significant reduction was seen due 
to ENR in PBS, SDS or FA extracted Aβ1-42 levels from any of the examined brain 
regions. However, ENR increased SDS extracted Aβ1-42 in the HIPPO that trended 
towards significance (F(1,34)=3.514 p=0.071) (Figure 6.16 B, D,F).  No 
combination treatment effect was seen with VAC and ENR, except for a decrease 
in SDS extractable Aβ1-42 in the PFCTX that trended towards significance 
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(F(1,34)=3.461 p=0.073) and a significant increase in PBS extractable Aβ1-42 in the 
HIPPO (F(1,34)=4.529 p=0.042).  These results suggest that the VAC reduced 
soluble and insoluble levels of Aβ1-42 in the PFCTX and OCTX.  Additionally, the 
combination treatment may have been effective in breaking down SDS extractable 
Aβ1-42 into a more soluble state leading to increased PBS extractable Aβ1-42. 
Aβ1-40 
In addition to Aβ Aβ1-42, levels of soluble and insoluble forms of Aβ1-40 were 
also measured. No significant decrease was seen due to VAC on Aβ1-40 in any 
fraction from the PCTX. There was a significant decrease in Aβ1-40 extractable by 
FA in the PFCTX (F(1, 34)=8.790  p= 0.006) and OCTX (F(1, 34)= 3.914 p= 0.057) 
(Figure 6.17 E). However, no significant reduction due to VAC was seen in PBS or 
SDS extractable Aβ1-40 in either of these regions (Figure 6.17 A and C).  An 
increase was seen in PBS extracted Aβ1-40 due to VAC in the HIPPO (F(1, 34)= 
5.433 p= 0.027) (Figure 6.17 A).  ENR had no effect on increasing or decreasing 
PBS, SDS, or FA extractable Aβ1-40 in any of the brain regions of interest (Figure 
6.17 B, D, F).  Additive effects of VAC and ENR were only seen with increasing 
SDS extractable Aβ1-40 in the PCTX (F(1,34)=6.150 p=0.019) and HIPPO 
(F(1,34)=12.465 p=.001).  These results suggest that the VAC as well as 
combination treatment may have been effective in breaking down FA extractable 
Aβ1-42 into a more soluble state leading to increased levels of PBS (VAC) or SDS 
(combo) extractable Aβ1-40. 
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Aβ42/40 Ratio 
The ratio of Aβ42/40 was calculated as an indicator of AD pathology and 
onset of the disease (95, 217).  A high Aβ42/40 ratio would indicate a greater 
abundance of Aβ1-42 than Aβ1-40, while a low Aβ42/40 ratio would indicate greater 
Aβ 1-40 levels in the brain.  We hypothesized a lower Aβ42/40 ratio in the VAC 
animals since animals were vaccinated with fibrillar Aβ1-42 and a reduction of Aβ1-
42 was expected.  No significant changes were seen in the ratio of Aβ42/40 in the 
PBS, SDS, and FA extracted samples from the PCTX or OCTX (Figure 6.18 A, C, 
E).  There was a significant decrease due to VAC seen in PBS (F(1, 34)= 15.732 
p= <0.005) and SDS (F(1, 34)=29.668 p= <0.005) extractable Aβ42/40 ratio in the 
PFCTX (Figure 6.18 A and C).  No increase or decrease due to ENR alone was 
observed (Figure 6.18 B, D, F). However, a decrease in the ratio is found in 
combination treatment of VAC and ENR in SDS extractable Aβ42/40 ratio 
(F(1,34)=5.994 p=0.020).  Interestingly, in the HIPPO, no increase or decrease 
due to VAC was found, but a significant increase due to ENR was detected in PBS 
extracted Aβ42/40 ratio (F(1,34)=5.101 p=0.031) (Figure 6.18 B). There is also an 
additive effect due to VAC and ENR in increasing PBS extractable Aβ42/40 ratio 
(F(1,34)=5.066 p=0.032) and increasing SDS extractable Aβ42/40 ratio 
(F(1,34)=7.668 p=.010).  These results suggest that the ratio of Aβ42/40 was overall 
reduced in soluble extracts of the PFCXT due to VAC and the combination of VAC 
ENR.  In the HIPPO, an increase in PBS extracted Aβ42/40 is seen which could 
suggest the breakdown of less soluble forms seen in the SDS or FA extracts into 
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more soluble Aβ seen in the PBS extract.  Collectively these results support the 
decrease in plaque loads seen in the PFCTX and HIPPO. 
Microhemorrhages 
Based upon previous studies  in transgenic mice (320, 335, 482-484) and 
human clinical trials (459) we hypothesized that C/V and E/V groups may have 
more microhemorrhages than the C/C and E/C groups due to the vaccine. To 
detect increased microhemorrhages, we stained sections from the PFCTX, OCTX, 
and HIPPO brain regions using Prussian blue, which detects iron in the 
extracellular matrix.  Counts of the number of microhemorrhages were used to 
detect treatment associated differences. 
The total number of bleeds across all brain regions ranged between 0 and 
23.  The most bleeds was seen in the PFCTX having a range from 1 to 10 bleeds, 
with the exception of one dog having 17 bleeds.  This canine in particular was a 
female, started the study at the age of 11.6 years, and was in the E/C treatment 
group.  The OCTX had similar bleed counts ranging from 0 to 7.  Fewer bleeds 
were seen in the HIPPO with a range of 0 to 3, with the exception of two dogs that 
had 7 and 23 bleeds.  The animal that experienced 7 bleeds was a male, started 
the study at the age of 12.3 years, and was in the C/C group.  The other dog that 
experienced 23 bleeds in the HIPPO was a female, started the study at the age of 
10.7 years, and was part of the E/V treatment group.  Further, if a dog did show a 
bleed in the HIPPO, it usually occurred in the CA3 region compared to area CA1 
or dentate gyrus. Neither ENR (χ2(1)=0.025 p=0.876) (data not show) nor VAC 
(χ2(1)=0.350 p=0.554) (Figure 6.19) significantly increased microhemorrhage 
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frequency in the PFCTX.  Additionally no individual group effect was seen on 
increasing the number of microhemorrhage frequency (χ2(3)=0.984 p=0.805) 
(Figure 6.20). There was also no change in the microhemorrhages in the HIPPO 
due to ENR (χ2(1)=0.355 p=0.551) (data not shown), VAC (χ2(1)=0.078 p=0.780) 
(Figure 6.19), or individual group (χ2(3)=0.853 p=0.837) (Figure 6.20).  In the 
OCTX, however, there was a statistically significant increase in microhemorrhages 
due to VAC (χ2(1)=6.501 p=0.011) (Figure 6.19) and group effect (χ2(3)=8.372 
p=0.039) (Figure 6.20).  Though an increase in bleeds was statistically seen due 
to VAC, neither the C/V nor E/V treatment groups show more microhemorrhages 
than the C/C animals (Figure 6.20).  However fewer microhemorrhages were seen 
in the E/C animals in the occipital cortex compared to C/V animals (Figure 6.20). 
It is possible that this decrease in bleeds of the E/C group (non VAC animals) could 
have led to the statistically apparent higher frequency of bleeds due to VAC. No 
increase in the number of microhemorrhages was observed due to a combination 
treatment effect in the occipital cortex. 
Comparison of Microhemorrhages Over Time Due to Treatments 
With the finding that E/C group had fewer bleeds in the OCTX compared to 
the other treatment groups and C/C group, we wanted to determine whether ENR 
was reducing the number of bleeds seen or having a maintenance effect as 
observed with plaque loads To do this we used the same 10 archive cases as used 
for plaque load analysis that were age matched to study dogs at the start of the 
study (10.5-13.6 years) (Pre-Treatment).  We stained PFCTX and OCTX tissue 
sections from these pre-treatment dogs with Prussian Blue. 
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The total number of bleeds in the PFCTX from this pre-treatment group of 
dogs ranged from 1 to 8, similar to numbers seen in the treatment groups and 
control group.  Statistically, there was no group difference in microhemorrhage 
counts in the PFCTX between the pre-treatment group and the four study groups 
(χ2(4)=1.103 p=0.894) (Figure 6.21).  In the OCTX, pre-treatment dogs only 
showed 0 to 3 microhemorrhages compared to the 0 to 7 range seen in the study 
dogs.  There was the exception of one pre-treatment dog that had 5 bleeds.  There 
was a group difference in microhemorrhage frequency between the groups 
including the Pre-Treatment group (χ2(4)=15.400 p=0.004) (Figure 6.21).  
Additionally, the pre-treatment group showed approximately the same number of 
microhemorrhages as the E/C treatment group (Figure 6.21).  While the C/C, C/V, 
and E/V treatment groups do not look to differ in number of bleeds, they do appear 
significantly higher than the pre-treatment and E/C groups.  This would suggest 
that the E/C treatment is having a maintenance or protective effect against 
microhemorrhages in the occipital cortex while all other treatment groups 
experience more bleeds with age independently of the VAC. 
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Figure 6.1.  Landmark Discrimination Learning.   
At  Landmark 0, among, dogs that received ENR, dogs that received ENR 
with VAC (E/V) had higher error scores than dogs receiving ENR only  (E/C) 
(t(16)=2.7 p=0.016).  No group effect was seen for Landmarks 1,2, and 4.  Overall, 
higher error scores occurring as the landmark distance (and thus task difficulty) 
increased (F(3, 42)=2.8 p=0.05). 
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Figure 6.2. Variable distance landmark.   
Dogs that received both VAC and ENR (E/V) did not differ in error scores for 
the variable distance landmark task compared to those receiving only ENR (E/C).  
Distance also had no effect on error scores during this task.     
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Figure 6.3. Discrimination and reversal learning over time. 
 (A) In discrimination learning, error scores increased over time in all groups 
(F(2,32)=3.4 p=0.05). No effect of the vaccine or of the behavioral enrichment 
alone was seen, however there was a significant effect of the combination 
treatment group (F(2, 32)=4.0 p=0.03). The combination treatment group had the 
lowest error scores. (B) Reversal learning also indicated an increase in error 
scores over time in all groups (F(2,30)=10.7 p<0.0005) 2 p=0.34).  No treatment 
effects were seen on error scores over time for VAC, ENR, or the combination 
treatment.  E/V treatment group had the highest error scores on reversal learning.  
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Figure 6.4. Variable delay spatial memory task. 
(A) No difference between treatment groups was seen in the accuracy of 
performance across increasing delay intervals on the spatial memory task when 
tested at baseline. (B) When re-tested 9.4 months into treatment, there was no 
improvement observed due to VAC or ENR treatment alone or in combination.  (C)  
Testing after 18.1 months into treatment indicated an interaction between delay 
interval and accuracy on the spatial memory task in the combination treatment 
group (F(2,38)=3.62 p=0.04). However, this may be due to the poor accuracy of 
the E/C and C/V groups during the 20s delay.  (D,E,F) A decrease in accuracy 
over time was seen for each delay interval (20 second delay, F(2,36)=16.12 
p<.0005; 70 second delay, F(2,36)=5.51 p=0.008; 110 second delay, 
F(2,36)=17.32 p<.0005).   
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Figure 6.5.  Anti-Aβ antibody titers over time as a function of treatment. 
IgG response was measured in the serum of all animals over multiple 
timepoints from baseline to euthanasia.  VAC animals developed an anti- Aβ IgG 
response over time (F(1,19)=12.5 p=0.002) and was maintained as a result of the 
active vaccine (A).  When observing all treatment groups, both VAC groups (C/V 
and E/V) developed an antibody response and maintained it (B). However the E/V 
response to the vaccine was delayed and did not reach the same maximum titers 
as observed in dogs receiving the vaccine alone C/V.  
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Figure 6.6.  Change in average CSF Aβ1-40 over the course of treatment. 
CSF Aβ1-40 was measured in all dogs across three time points through the 
duration of treatment.  ENR led to a significant increase in CSF Aβ1-40 
(F(1,22)=5.76 p=0.03) (*) (A).  VAC neither increased nor decreased the levels of 
Aβ1-40 in CSF with the time points that were collected (B).  
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Figure 6.7. Change in average CSF Aβ1-40 over course of study in all four treatment 
groups. 
No change in CSF Aβ1-40 was seen over time in any treatment group.  
However, the combination treatment group E/V did have the greatest increase in 
CSF Aβ1-40 by the end of the study. 
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Figure 6.8. Change in average CSF Aβ1-42 over the course of treatment.   
CSF Aβ1-42 was measured in all dogs across three time points through the 
duration of treatment.  No systematic effects were seen due to any treatment (A, 
B).    
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Figure 6.9. Change in average CSF Aβ1-42 over course of study in all four 
treatment groups.   
None of the treatments significantly changed CSF Aβ1-42 over time.  
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Figure 6.10.  Average Aβ1-42 plaque loads in PFCTX, PCTX, OCTX, and ECTX 
regions of the brain.   
Aβ1-42 plaque loads were reduced in most brain regions of VAC animals (C/V 
and E/V) (PFCTX (F(1, 34)= 33.04 p= <0.001); OCTX (F(1, 34)= 14.92 p= 0.001); 
PCTX (F(1, 33)= 14.06 p= 0.001) (*).  No additive effect was seen due to the 
combination of VAC and ENR (E/V).  Though not as low as the C/V or E/V groups, 
E/C animals did have lower loads of Aβ1-42 plaques than the C/C group in the 
PFCTX (Bonferroni, p=0.02).  
* * 
* 
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Figure 6.11. Average total Aβ plaque loads in PFCTX, PCTX, OCTX, and ECTX 
regions of the brain. 
Total Aβ plaque load were reduced in the brains of VAC animals (C/V and 
E/V) (PFCTX, F(1,34)= 52.91 p= <0.001; OCTX, F(1,34)= 13.65 p= 0.001; PCTX, 
F(1,33)= 10.70 p= 0.003; ECTX, (F(1, 34)= 6.60 p= 0.02).  No additive effect was 
seen due to the combination of VAC and ENR (E/V).  Lower levels of total Aβ 
plaque loads were observed in the E/C group compared to the C/C group in the 
PCTX (Bonferroni, p=0.06).  
* 
* * 
* 
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Figure 6.12. Average pyro glutamate modified Aβ (AβpE3) plaque loads in PFCTX, 
PCTX, OCTX, and ECTX regions of the brain. 
Plaque levels of AβpE3 were overall lower than Aβ1-42 and total Aβ plaque 
levels in all regions of the brain.  Though post-translationally modified, VAC was 
able to reduce plaque loads containing this more toxic form of Aβ in the PFCTX 
(F(1, 30)= 10.00 p= 0.004) and PCTX (F(1, 29)= 6.50 p= 0.02).  E/C animals did 
not differ in AβpE3 plaque loads from those of the C/C treatment group in any brain 
region. 
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Figure 6.13.  Changes in average Aβ1-42 plaque loads between Pre-
Treatment animals and treated study animals in PFCTX and PCTX regions of the 
brain.  
 When comparing pretreatment animals to C/C, there is a significant increase 
in Aβ1-42 plaque load with age (PFCTX, Bonferroni, p=0.050; PCTX Bonferroni, 
p=035).   Pre-treatment animals did not differ from E/V animals suggesting a 
possible maintenance of plaque loads over time due to ENR (PFCTX, Bonferroni 
p=1.000; PCTX, Bonferroni, p=1.000).   
* * 
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Figure 6.14. Changes in average total Aβ plaque loads between pre-treatment 
animals and study animals in PFCTX and PCTX regions of the brain.   
Pre-treatment animals had lower levels of total Aβ plaque loads compared to 
control (C/C) animals in the PFCTX (Bonferroni, p=0.014), while there was no 
difference compared to E/C animals (Bonferroni, p=1.000).  This lack of change in 
the E/C group suggests that ENR could be counteracting the natural age 
dependent increase in total Aβ plaque loads as seen in C/C animals. No systematic 
changes were seen in the PCTX for total Aβ plaque loads.  
* 
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Figure 6.15.  Changes in average AβpE plaque loads between pre-treatment 
animals and study animals in PFCTX and PCTX regions of the brain.  
Significant group effects are seen in AβpE plaque loads between pre-
treatment animals and treated study animals in both the PFCTX (F(4, 44)= 9.752  
p= 0.009) and PCTX (F(4, 44)=3.321 p= 0.020).  There was very little AβpE in pre-
treatment dogs. While VAC reduced AβpE in treated animals compared to C/C or 
E/C groups, levels do not return back to those seen before the start of the study 
as represented by the pre-treatment group. 
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Figure 6.16. Soluble and insoluble brain Aβ1-42 as a function of treatment.   
Higher levels of FA extractable brain Aβ 1-42 were seen compared to PBS 
and SDS across all groups. VAC reduced all forms of extractable Aβ1-42 in the 
PFCTX (PBS, F(1, 34)= 2.518 p= 0.016; SDS, F(1, 34)=31.244  p= <0.005; FA, 
F(1, 34)=5.610  p= 0.024)and OCTX (PBS, F(1, 34)= 5.782 p= 0.023; SDS, F(1, 
34)= 14.451 p= 0.001; FA, F(1, 34)= 3.914 p= 0.057) (A, C, E).  No change in 
soluble or insoluble Aβ was seen due to ENR (B, D, F), except for an increase in 
SDS extractable Aβ1-42 in the HIPPO (F(1,34)=3.514 p=0.071) that trended 
towards significance (D). 
 
  
  
112 
 
 
  
* 
* 
* 
  
113 
Figure 6.17.  Soluble and insoluble brain Aβ1-40.   
VAC increased PBS extracted Aβ1-40 in the HIPPO (F(1, 34)= 5.433 p= 0.027) 
(A), while it reduced insoluble FA extractable Aβ1-40 in the PFCTX (F(1, 34)=8.790  
p= 0.006) and OCTX (F(1, 34)= 3.914 p= 0.057) (E).   No change in soluble or 
insoluble Aβ was seen due to ENR (B, D, F).    
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Figure 6.18.  Soluble and insoluble brain Aβ1-42/ Aβ1-40 Ratios  
VAC decreases PBS (F(1, 34)= 15.732 p= <0.005) extractable Aβ 42/40 ratio 
in the PFCTX(A), ENR increased PBS extracted Aβ 42/40 ratio (F(1,34)=5.101 
p=0.031) in the HIPPO (B). SDS extractable Aβ 42/40 ratio in the PFCTX was 
reduced by VAC (F(1, 34)=29.668 p= <0.005) (C).  No increase or decrease due 
to ENR was observed in SDS extractable Aβ 42/40 ratio (D).  FA extractable Aβ 
42/40 ratio was neither increased nor decreased by VAC or ENR (E, F).  
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Figure 6.19.  Microhemorrhages frequency in the PFCTX, OCTX, and Hippo 
regions of the brain in VAC treated animals compared to non VAC treated animals. 
 VAC does not cause an increase in microhemorrhages in the PFCTX or 
Hippo regions of the brain.  However, VAC appears to increase the number of 
microhemorrhages in the OCTX but there was significant individual variability 
(χ2(1)=6.501 p=0.011). 
  
* 
  
117 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.20.  Microhemorrhage occurrence in the PFCTX, OCTX, and Hippo 
regions of the brain as a function of treatment group. 
No increases in microhemorrhage frequency in the PFCTX or Hippo were 
seen as a consequence of treatment.  While VAC increases bleed events in the 
OCTX (χ2(1)=6.501 p=0.011), the number of bleeds observed in VAC animals (C/V 
and E/V groups) does not differ significantly from the control animals (C/C) 
(Bonferroni- C/V, p=0.852; E/V, p=1.000).  However, the E/C treatment group 
showed fewer microhemorrhages in the OCTX than the C/C group (Bonferroni, 
p=0.071) suggesting that ENR may be protective in that region of the brain.  
* 
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Figure 6.21. Microhemorrhage occurrence in the PFCTX and OCTX regions of the 
brain in pre-treatment and study animals. 
In the PFCTX there were no differences in microhemorrhages between any 
of the treatment groups.  However, in the OCTX, pre-treatment and E/C animals 
trends towards having fewer microbleeds than C/C and VAC dogs. Since E/C 
animals appear to show the same frequency of microbleeds as the pre-treatment 
animals, we suggest that the ENR is maintaining brain health and preventing 
microhemorrhages that may naturally occur with age. 
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CHAPTER SEVEN: Discussion  
Previous human clinical trials using active vaccination with fibrillar Aβ1-42, 
though discontinued due to cases of meningoencephalitis, showed evidence of 
reduced Aβ pathology within the brain (135, 181).  Consequently, passive 
immunization approaches that eliminate the possibility of the previous adverse 
events have been and are currently being investigated in patients with mild to 
moderate AD; these immunotherapies reduce Aβ pathology and show modest 
reductions in rates of cognitive decline (101, 103, 366, 367). While these passive 
immunotherapies do not lead to meningoencephalitis, they have caused 
microhemorrhaging in several patients as seen by magnetic resonance imaging 
(368, 420).  Our lab has investigated active immunization in aged canines using 
an adjuvant that is safe for use in mice and humans having few adverse effects 
(24, 83, 177, 246).  In a previous study  in aged canines,  active vaccination with 
fibrillar Aβ1-42 using Alum as an adjuvant reduced Aβ pathology in the brain and 
helped maintain executive function without causing adverse effects such as 
meningoencephalitis as seen with past active vaccinations (177). However, 
improved cognition in response to the vaccine was not observed in the canine 
study as reported in transgenic mouse studies (198, 286). Thus, it is possible that 
the vaccine alone and reduction of Aβ was insufficient to improve cognition in aged 
dogs with neuropathology. We hypothesized that adding a second intervention that 
would lead to neuronal repair may be beneficial when combined with the vaccine. 
We focused on behavioral enrichment as a second “arm” to this study. 
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Behavioral enrichment, consisting of exercise, cognitive enrichment, social 
engagement, and environmental enrichment, is being evaluated in clinical trials for 
AD in humans and animal models. Exercise and environmental enrichment 
improve learning in rodents but shows variability between studies in AD mouse 
models (17, 80, 239).  In humans, behaviorally enriched lifestyles, involving 
exercise, cognitive enrichment, and social engagement, helps reduce brain 
atrophy with age and reduces risk of dementia (165, 274). Furthermore, in canines, 
ENR improves cognitive function without affecting Aβ levels in the brain (71, 485).  
While immunotherapies reduce Aβ pathology in humans and animals as well as 
aid in cognitive maintenance, ENR improves cognition and reduces risk of 
dementia but has variable outcomes on levels of brain Aβ.  This study sought to 
combine active VAC with ENR predicting they would build upon one another and 
lead to greater cognitive improvement as well as decreased Aβ pathology 
compared to each individual treatment alone. 
One aspect of the combination therapy we wanted to test was its effects on 
cognition.  Based on our previous studies, ENR improves overall cognition in aged 
canines (71, 485).  However, in a previous canine active vaccine study, no 
improvements in cognition were observed (177). We had hypothesized that our 
study animals receiving ENR only or VAC only would show similar results to past 
studies but animals receiving both ENR and VAC would exhibit greater cognitive 
improvements.  Our results however, indicated no systematic effects by any 
treatment on improving cognition.  The lack of cognitive improvement in the E/C 
group came as a surprise.  It was noted however, that all tested animals actually 
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performed better with lower error scores at baseline than dogs in past studies did 
during their baseline testing.  Also, housing protocols and the diet now provided 
for research canines has improved substantially since our last ENR study.  It is 
possible that the housing conditions have improved enough that an ENR threshold 
has been met between all treatment groups just through these conditions where 
no additional cognitive benefits can occur even with added social engagement or 
cognitive enrichment.  Results from the current study strongly suggest that 
reversing age-associated and Aβ-dependent cognitive decline is challenging and 
prevention may be more beneficial. Results from our neurobiological studies 
support this conclusion as will be discussed next. 
After 19 months of treatment with the active vaccine of fibrillar Aβ1-42, VAC 
animals had increased antibody titers against fibrillar Aβ1-42.  In C/V animals, this 
response was first seen at 4 weeks after treatment, while the E/V treated dogs 
experienced a delayed response at 2 months.  While both groups receiving VAC 
maintained antibody levels through the rest of the study, the maximum response 
of the E/V treatment group never reached that of the C/V treatment group.  It is 
possible that ENR in the combination treatment suppressed the immune response 
initiated by the vaccine causing a lower maximum antibody response but was still 
sufficient to reduce brain Aβ to the same extent as the C/V group.  Overall, the 
elevated levels of anti- Aβ1-42 antibodies indicate that the active vaccination was 
successful in initiating the production of antibodies against fibrillar Aβ1-42.  This 
result mirrors that of the human trials using active vaccination, where patients 
showed an antibody response between one and two months after treatment (181).   
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CSF Aβ levels correlate with disease in patients with AD who show lower 
CSF Aβ levels than non-demented individuals (for review, see (14)).  To monitor 
Aβ changes throughout treatment, CSF samples were collected before treatment, 
12 months into treatment, and at euthanasia.  We hypothesized that VAC animals 
would have higher Aβ levels than non-VAC animals. These expected results would 
suggest the vaccine was succeeding in removing the Aβ from the brain and moving 
it into the periphery.  However, VAC did not lower or raise CSF Aβ1-42 or Aβ1-40 
compared to dogs that did not receive VAC.  Several contributing factors may exist 
for these unexpected results.  Samples were only able to be drawn at two time 
points before euthanasia.  It is possible that levels of CSF Aβ may have become 
elevated at some time between the baseline and 12 months collection time points 
as Aβ was cleared from the brain. This elevation would then be followed by a 
reduction once a majority of Aβ was removed from the brain and periphery.  
Essentially, once Aβ was cleared from the brain and into the periphery, Aβ would 
also be removed from the CSF. This possible mechanism could have been 
captured had additional time point collections of CSF been made.  Unfortunately, 
in order to collect CSF, the animals must be sedated, which can be physiologically 
stressful for aged animals.  For this reason, CSF draws were limited to three 
spaced out collection time points.  
While VAC did not reduce CSF Aβ1-42 or Aβ1-40, ENR did increase CSF Aβ1-
40.  As discussed earlier in Chapter 2, Aβ1-40 is the prominent isoform of Aβ peptide 
involved in amyloidosis in the vasculature of the brain (324, 389, 498).  One 
possible explanation for the increased CSF Aβ1-40 is that the exercise component 
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of the ENR improved blood perfusion and cerebrovascular health and aided in the 
clearance of Aβ deposited in the vasculature to the periphery.  Additionally, this 
increase in CSF Aβ1-40 was selective and not seen with Aβ1-42.  Since Aβ1-42 tends 
to form plaques in the parenchyma of the brain rather than within blood vessels, 
this lack of effect by ENR on CSF Aβ1-42 further supports the idea of ENR acting 
specifically on the cerebrovasculature. (324, 389, 477). 
Several active and passive immunotherapies studied as a therapeutic for AD 
have shown positive results in reducing Aβ plaque pathology in both animal models 
and patients with AD (94, 177, 341, 367, 368, 381, 403, 438).  In the present study, 
use of active immunization with fibrillar Aβ1-42 in combination with ENR to treat 
aging canines also reduces Aβ pathology in several regions of the brain.  VAC 
treated dogs, including both the C/V and E/V treatment groups, had decreased Aβ 
plaque loads compared to non-immunized animals in the PFCTX (Aβ1-42 and total 
Aβ), OCTX (Aβ1-42 and total Aβ), PCTX (Aβ1-42 and total Aβ), and ECTX (total Aβ) 
regions of the brain.  In addition, AβpE3, post-translationally modified Aβ, was 
reduced in the PFCTX and PCTX regions of the brain in VAC animals.  Previous 
vaccine studies using the canine model have not explored the vaccine’s potential 
in reducing post-translationally modified Aβ.  Post-translationally modified Aβ, 
including AβpE3, has shown to be more toxic and involved in the initial stages of 
the disease thereby making it a crucial therapeutic target for clearance in a clinical 
setting (8, 162, 362, 383, 385, 487).       
The previous ENR study in aged canines did not exhibit any kind of reduction 
in Aβ pathology in response to treatment (322).  Interestingly, in the current study 
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ENR showed a trend towards reducing Aβ1-42 in the PFCTX.   ENR led to reduced 
total Aβ plaque loads in the PFCTX and PCTX.  However, ENR did not show any 
treatment effects in reducing AβpE3.    With this finding we became curious if the 
lower Aβ pathology was due to a clearance effect or maintenance effect due to the 
ENR.  Since this reduction due to ENR seen in our study was not as great as that 
seen by VAC, we hypothesized that the ENR had a maintenance effect on Aβ 
plaque loads rather than a clearance effect.   
To test if ENR was having a maintenance or clearance effect on plaque loads, 
we used PFCTX and PCTX brain tissue (regions that appeared to have the 
greatest treatment effect by ENR) from 10 canine cases from our archive tissue 
inventory.  Dogs were selected at matched ages to the baseline ages of the 
treatment study animals.  These pre-treatment dogs represented the average 
plaque loads of the treatment study dogs prior to the start of treatment, providing 
a means of comparing change in plaque loads with age (with C/C group dogs) and 
with treatment (with E/C, C/V, and E/V group dogs).   
Results showed that pre-treatment dogs exhibited significantly lower plaque 
loads than C/C dogs for all types of Aβ examined illustrating the increase of plaque 
loads in the canine with age over time.  Aβ1-42 plaque loads of the PFCTX in pre-
treatment dogs most resembled that of the E/C treatment group suggesting that 
the effects seen by ENR were likely maintenance of plaque loads in treated dogs 
rather than a clearance of Aβ plaques.  This maintenance could have either been 
a decreased rate of Aβ accumulation or slowing of Aβ accumulation.  Aβ1-42 plaque 
loads in the PCTX of the pre-treatment animals fell between the E/C treatment 
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group and VAC animals. However, the E/C group loads were still lower than that 
of the C/C group.  It is likely that the ENR was able to slow the rate of Aβ1-42 plaque 
formation in the PCTX while VAC cleared plaque loads.  A similar effect is 
suggested with total Aβ plaque loads in the PFCTX and PCTX.  Unlike the Aβ1-42 
and total Aβ plaque loads, AβpE3 average plaque load for the pre-treatment group 
was significantly lower than all treatment groups on the present study.  ENR 
appears to have no effect on AβpE3 plaque loads, while the VAC reduced/cleared 
this post-translationally modified form of Aβ (VAC animals). The lack of change in 
AβpE3 plaque loads suggests that ENR was not affecting preexisting Aβ, but 
rather the further accumulation of Aβ plaques.  These results support ENR having 
a maintenance effect rather than enhancing clearance. 
Aβ found in the periphery is of soluble form, however, both soluble and 
insoluble Aβ are found in the brain (262, 294, 390, 473).  Plaque loads do not 
provide us with information regarding the changes in soluble as compared to 
insoluble Aβ. Though insoluble Aβ primarily makes up plaque pathology, this form 
of Aβ may not all be aggregated into plaque and can also be found in blood 
vessels.  Additionally, plaque loads do not provide insight on soluble Aβ levels 
since this form of Aβ is not associated with plaques (262, 294, 390, 473).  To further 
investigate the combination treatment effects of the present study serial extracted 
soluble and insoluble Aβ was measured in all treatment groups.  We found that 
VAC reduced both soluble (PBS and SDS extracts) and insoluble (FA extract) Aβ1-
42 from the PFCTX and OCTX compared to non VAC dogs.  Our findings confirmed 
the earlier mentioned clearance of Aβ1-42 plaques seen by VAC in these brain 
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regions.  While we saw a reduction in Aβ1-42 plaques that trended towards 
significance in the PFCTX due to ENR, we did not see any effect by ENR on 
reducing FA extracted insoluble Aβ1-42 in this brain region or any other examined 
region supporting the hypothesis of maintenance and not clearance of Aβ 
pathology. 
We did not see a reduction in FA extracted Aβ1-40 due to VAC, however, an 
increase of PBS extracted Aβ1-40 was seen.  This increase in soluble Aβ1-40 could 
be the result of breaking down plaques by the VAC into more soluble forms of Aβ.  
While we saw an increase in soluble Aβ1-40 in the CSF of ENR treated dogs, we 
did not see the expected decrease in insoluble or soluble Aβ1-40 in any brain region 
of these dogs.  As discussed earlier, the increase in CSF Aβ1-40 may have been 
due to the clearance of deposited Aβ in the cerebrovasculature by ENR benefits 
on vascular health. If this is the case, then any insoluble Aβ1-40 deposited in blood 
vessels would be broken down into a soluble state and be more readily cleared 
from the brain and into the periphery than that of which is deposited in the 
parenchyma of the brain.  While this clearance of vascular deposited Aβ could lead 
to a noticeable increase in peripheral Aβ1-40, as seen in the CSF of ENR animals, 
it may not be enough to indicate an apparent decrease in insoluble brain Aβ1-40.  
This would explain the lack of difference in the serial extracted Aβ in the brain due 
to ENR. 
Using the measurements of Aβ1-42 and Aβ1-40 we calculated the Aβ 42/40 
ratio. Generally Aβ 42/40 ratio is an indicator of AD pathology and onset of the 
disease (95, 217).  In dogs, it is expected that this ratio would be higher with age 
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as pathology and cognitive decline progress.  Since the VAC dogs in our study 
received vaccinations of fibrillar Aβ1-42 and had shown reduced levels of Aβ1-42, we 
hypothesized that the Aβ 42/40 ratio would be lower in VAC treated animals than 
non-treated animals.  Aβ 42/40 ratios for PBS and SDS extractable Aβ were lower 
in the PFCTX of VAC treated animals.  With these results we could conclude that 
the VAC was most productive in reducing Aβ pathology specifically in the PFCTX, 
which is portrayed in the reduction of plaque forms and serial extracted Aβ in the 
PFCTX.  While no change was seen in Aβ 42/40 ratios for the PCTX, OCTX, or 
HIPPO of the VAC animals, these regions did still show reduced plaque loads or 
soluble and insoluble Aβ.  
While both VAC and ENR had their respective treatment effects on CSF Aβ, 
Aβ plaque load, serially extracted Aβ, and overall reduction of Aβ pathology, no 
significant additive effects were seen in the combination treatment group in further 
reducing Aβ pathology.  Statistically by two way ANOVA, there was a significant 
additive effect of VAC and ENR in decreasing Aβ1-42 plaque load in the PFCTX, 
decreasing SDS extractable Aβ1-42 and Aβ 42/40 ratio in the PFCTX, increasing 
PBS extractable Aβ1-42 and Aβ 42/40 ratio in the HIPPO, and increasing SDS 
extractable Aβ1-40 in the PCTX and HIPPO.  However, by post hoc the E/V 
treatment group did not have greater effects than the C/V group.  In the presence 
of active vaccine, the ENR provides no additional benefit.   
The results of our study further support the ability of active vaccination with 
fibrillar Aβ1-42 combined with Alum to reduce Aβ pathology in aged canines.  
Additionally the vaccine in our study does not promote adverse effects similar to 
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the meningoencephalitis that was seen in the human clinical trials using an active 
vaccine with QS-2 in polysorbate 80 as an adjuvant.  However, there was still the 
concern of intracerebral microhemorrhages due to the use of immunotherapies for 
treatment of AD.  Such an increase in microhemorrhages could increase risk of 
intracerebral microhemorrhage and further cognitive impairment (39, 469).  We 
examined the frequency of microhemorrhages in the PFCTX, OCTX, and HIPPO 
regions of the brains in all study dogs along with the added pre-treatment archive 
cases in order to determine if an increase in microhemorrhages would occur with 
the use of the active vaccination with fibrillar Aβ1-42 in Alum.  Microhemorrhages 
appeared to be more frequent in the PFCTX and OCTX than the HIPPO of study 
dogs.  The PFCTX and OCTX are regions of the brain where Aβ deposition is 
thought to occur first with age (18, 50-52, 445). Since microhemorrhages do occur 
with age and with greater Aβ deposition in the vasculature of the brain, it was not 
surprising to see these regions having the greater number of microhemorrhages 
compared to the HIPPO. Neither VAC nor ENR led to an increase in 
microhemorrhages in the PFCTX or HIPPO.  There was a statistically significant 
increase in microhemorrhages in the OCTX due to VAC.  However, the C/V and 
E/V treatment groups did not differ in microhemorrhage occurrence compared to 
the C/C group.  What was apparent was the lower number of OCTX 
microhemorrhages in the E/C treatment group compared to the other groups.  It’s 
possible that this lower frequency of microhemorrhages in the E/C drove the 
statistical increase in microhemorrhages due to VAC since the E/C group is 
considered part of the non-VAC animals.  Using the same baseline age match 
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archive cases that were in the plaque load analysis, we were able to determine if 
the lower microhemorrhage frequency in the E/C group was due to a maintenance 
effect of treatment. Pre-treatment dogs showed a similar frequency of 
microhemorrhages in the OCTX as the E/C treatment group. This observation 
suggests that ENR shows maintenance or protective effects against additional 
microhemorrhages while all other treatment groups experienced more bleeds with 
age independently of VAC. 
Although no significant or consistent cognitive benefits were detected in any 
treatment group, the active vaccine successfully produced antibody responses 
against fibrillar Aβ1-42.  Vaccinated animals also showed a reduction in overall Aβ 
pathology in multiple areas of the brain, while not showing an increase in CSF Aβ.  
Previous immunotherapy studies in animals or humans had investigated the 
potential ability to reduce modified Aβ pathology such as plaques consisting of 
AβpE3.  Here we show that active vaccination with fibrillar Aβ1-42 is successful in 
reducing a toxic and highly aggregated form of modified Aβ in the canine model.   
In addition to the vaccine treatment, those receiving ENR showed a lack of age-
associated increase in Aβ pathology that has not been reported in past ENR 
studies in dogs.   ENR led to an increase in CSF Aβ1-40 possibly suggesting ENR 
aiding in the clearance of deposited Aβ in the vasculature. ENR also slowed the 
age associated increase of Aβ1-42 plaque load in the PFCTX with treatment.  In the 
HIPPO, ENR decreased SDS extractable Aβ1-42 in the HIPPO.  As for the concern 
for potential adverse effects of immunotherapy for AD, no serious negative effects 
were seen and frequency of microhemorrhage occurrence was not increased with 
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the use of active vaccination with fibrillar Aβ1-42 in Alum. Additionally, we found that 
ENR may actually reduce the risk of microhemorrhages in the OCTX region.  While 
benefits of both VAC and ENR were experienced in reducing Aβ pathology, the 
combination of both treatments did not cause any additional benefit compared to 
using only single treatment of either VAC or ENR.  Additionally, no synergistic 
improvement was detected in cognitive function in the combination treatment 
group compared to individual treatment groups.  
Many therapeutic approaches have at best, modestly improved cognitive 
function in larger animal models of AD.  This lack of cognitive improvement is 
consistent with clinical trials with AD patients.  It is possible that once Aβ has begun 
its damage to neurons it is challenging to reverse it and restore cognition that has 
already been compromised.  Either alternative therapeutic approaches need to be 
explored, or treatment may need to be initiated earlier as a preventative approach 
before the Aβ pathology begins or worsens.   
The combination treatment we use in this study may better serve as a 
preventative therapy for AD.  Our results from the ENR treatment strongly support 
a maintenance effect that likely works on a mechanism completely separate to that 
by which the VAC component of the combination therapy did.  While the ENR 
appears to be acting on the mechanism of Aβ accumulation, the VAC works by 
clearing pre-existing Aβ pathology.  Together, the combination treatment could be 
a viable therapeutic approach for the prevention of AD.  With the age of onset for 
AD pathology varying between individuals, determining a timeline for 
administration of a preventative treatment becomes difficult.  Using a combination 
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therapy approach such as ENR with VAC could target both the prevention of Aβ 
accumulation as well as the clearance of any likely little pre-existing Aβ pathology.  
This type of treatment approach could allow for some flexibility when determining 
a timeline for administering the treatment in a given individual.  Ultimately, the 
treatment could act early enough to prevent any possible irreversible damage 
being done to the neurons by the Aβ pathology and avoid resulting cognitive 
deficits.  
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CHAPTER EIGHT: Future Directions 
While the approach of using VAC in combination with ENR in this study did 
not lead to additive effects in reducing Aβ pathology or improving cognition in aged 
canines, we did see interesting and novel cerebrovascular benefits due to ENR 
that had otherwise not been seen in the previous canine study.  It would be of great 
interest to measure the amount of blood vessel Aβ pathology in the study animals 
and determine if there is a correlation between these levels and increased CSF 
Aβ1-40.  We would hypothesize that there would be a correlation between lower 
levels of blood vessel pathology and increased levels of CSF Aβ1-40 and that this 
correlation would be seen in animals receiving ENR.  Additionally, the changes in 
Aβ plaque pathology seen due to ENR indicate that a maintenance effect is likely 
occurring in ENR treated animals.  To further investigate this maintenance idea, α- 
and β-secretase activity could be measured. In a previous canine study exploring 
the effects of an antioxidant diet and ENR on Aβ load, α- secretase activity was 
increased in animals receiving ENR (322).  For the current study we would 
hypothesize that ENR is promoting α-secretase activity resulting in ENR animals 
having lower β-secretase activity and increased non-amyloidogenic processing 
compared to non-ENR animals.      
The focus of this study was to examine effects on cognition and Aβ pathology 
due to the combination treatment.  Other neurological changes that have 
previously been reported in past ENR studies have not yet been explored in these 
animals.  For instance, although neurogenesis was not increased with ENR in a 
previous aged canine study, neuron number in the hippocampus and the growth 
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factor BDNF are maintained and improved, respectively, in ENR treated dogs  
(116, 278, 279, 407).  Future directions of this project would be to explore these 
changes in the present study animals and comparing those in the E/V treatment 
group to all other groups. One could hypothesize that the both the E/C and E/V 
treatment groups would show higher levels of BDNF and potentially enhanced 
neuron survival and neurogenesis, with the E/V group experiencing greater 
improvement.   
It was noted that the VAC was successful in reducing modified Aβ, AβpE3, 
pathology that has been previously shown to be more toxic. Additionally, AβpE3 
correlates with the hyperphosphorylation of tau.  Though canines do not produce 
NFTs with age, they do show hyperphosphorylation of tau at sites that coincide 
with those affected in humans with AD.  It would be of interest to measure levels 
of soluble and insoluble tau in our treated canines and see if a correlation exists 
between these measures and the effects of VAC on AβpE3 plaque pathology.  One 
could hypothesize that levels of insoluble tau in C/C and E/C treatment groups 
would be higher than those of the C/V and E/V treatment groups. The effects of 
VAC in reducing AβpE3 pathology could lead to the de-hyperphosphorylation of 
tau or the prevention of additional hyperphosphorylated insoluble tau.  
As mentioned earlier, the combination approach tested in the current study 
may have exhibited greater additive effects, particularly on cognition, had the 
treatment been started at an earlier age in the canines.  As a future project, this 
combination treatment could be tested in canines around 7 to 8 years old, just as 
Aβ begins to accumulate.  At this age, Aβ pathology should be minimal and 
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cognitive changes would be predicted to be mild.  ENR started at this age would 
promote healthier brain aging as earlier studies have shown ENR improve 
neurogenesis and reduced neuronal loss (116, 408).  From our findings in this 
study, ENR should also reduce the risk of microhemorrhage occurrence which can 
contribute to cognitive decline. Additionally ENR prevented or slowed the rate of 
Aβ plaque accumulation and would be hypothesized to aid in preventing Aβ in 
younger canines.  With ENR and VAC acting on separate pathways, one could 
hypothesized the resulting immune response would further assist in preventing 
additional Aβ pathology and clearing out any pre-existing early Aβ plaque 
formation before any neuronal damage could occur. 
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